CA2634674A1 - Novel albumin-free factor viii formulations - Google Patents
Novel albumin-free factor viii formulations Download PDFInfo
- Publication number
- CA2634674A1 CA2634674A1 CA002634674A CA2634674A CA2634674A1 CA 2634674 A1 CA2634674 A1 CA 2634674A1 CA 002634674 A CA002634674 A CA 002634674A CA 2634674 A CA2634674 A CA 2634674A CA 2634674 A1 CA2634674 A1 CA 2634674A1
- Authority
- CA
- Canada
- Prior art keywords
- factor viii
- formulations
- sucrose
- temperature
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Abstract
A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
Description
Novel Albumin-Free Factor VIII Formulations BACKGROUND OF THE INVENTION
Factor VIII is a protein found in blood plasma which acts as a cofactor in the cascade of reactions leading to blood coagulation. A deficiency in the amount of Factor vIII activity in the blood results in the clotting disorder known as hemophilia A, an inherited condition primarily affecting males. Hemophilia A
is aurrently treated with therapeutic preparations of Factor VIII derived from human plasma or manufactured using recombinant DNA technology. Such preparations are administered either in response to a bleeding episode (on-demand therapy) or at frequent, regular intervals to prevent uncontrolled bleeding (prophylaxis).
Factor VIII is known to be-relatively unstable in therapeutic preparations. In blood plasma, Factor VIII is usually complexed with another piasma protein, von Willebrand factor (vWF), which is present in plasma in a large molar excess to Factor VIII and is believed to protect Factor VIII from premature degradation. Another circulating plasma protein, albumin, may also play a role in stabilizing Factor VIII in vivo. Cunently marketed Factor VIII preparations themfore primarily rely on the use of albumin and/or vWF to stabilize Factor VIII during the manufaGturing process and during storage.
The albumin and vWF used in cun-ently marketed Factor VIII preparations is derived from human blood plasma, however, and the use of such material has certain drawbacYs. Because a large molar excess of albumin compared to Factor VIII is generally added in order to increase the stability of the Factor VIII
in such prepamtions, it is difficult to characterize the Factor VIII protein itself in these preparations. The addition of human-derived albumin to Factor VIII is
Factor VIII is a protein found in blood plasma which acts as a cofactor in the cascade of reactions leading to blood coagulation. A deficiency in the amount of Factor vIII activity in the blood results in the clotting disorder known as hemophilia A, an inherited condition primarily affecting males. Hemophilia A
is aurrently treated with therapeutic preparations of Factor VIII derived from human plasma or manufactured using recombinant DNA technology. Such preparations are administered either in response to a bleeding episode (on-demand therapy) or at frequent, regular intervals to prevent uncontrolled bleeding (prophylaxis).
Factor VIII is known to be-relatively unstable in therapeutic preparations. In blood plasma, Factor VIII is usually complexed with another piasma protein, von Willebrand factor (vWF), which is present in plasma in a large molar excess to Factor VIII and is believed to protect Factor VIII from premature degradation. Another circulating plasma protein, albumin, may also play a role in stabilizing Factor VIII in vivo. Cunently marketed Factor VIII preparations themfore primarily rely on the use of albumin and/or vWF to stabilize Factor VIII during the manufaGturing process and during storage.
The albumin and vWF used in cun-ently marketed Factor VIII preparations is derived from human blood plasma, however, and the use of such material has certain drawbacYs. Because a large molar excess of albumin compared to Factor VIII is generally added in order to increase the stability of the Factor VIII
in such prepamtions, it is difficult to characterize the Factor VIII protein itself in these preparations. The addition of human-derived albumin to Factor VIII is
2 also perceived as being a disadvantage with respect to recombinantly-produced Factor VIII preparations. This is because recombinantly-derived Factor VIII
preparations, in the absence of such added albumin, would otherwise contain no human-derived proteins, and the theoretical risk of transmitting a virus would be reduced.
Several attempts to fonnulate Factor VIII without albumin or vWF (or with relatively low levels of these excipients) have been described. For example, U.S. Patent No. 5,565,427 (EP 508 194) to Freudenberg (assigned to to Beluingwerke) describes Factor VIII preparations which contain particular combinations of detergent and ,amino acids, specifically arginine and glycine, in addition to excipients such as sodium chloride and sucrose. The detergent, polysorbate 20 or polysorbate 80, is descn'bed as being present in amounts of between 0.001 to 0.5% (v/v), while arginine and glycine are present in amounts of between 0.01 to 1:nol/l. Sucrose is descrn'bed as being present in amounts of between 0.1 and 10=0. Example 2 of this patent asserts that solutions of (1) 0.75% sucrose, 0.4 M glycine, and 0.15M NaCI, and (2) 0.01 M sodium citrate, 0.08 M glycine, 0.016M lysine, 0.0025 M calcium chloride, and 0.4 M sodium ~. chloride were not stable in solution over 16 hours, whereas solutions of
preparations, in the absence of such added albumin, would otherwise contain no human-derived proteins, and the theoretical risk of transmitting a virus would be reduced.
Several attempts to fonnulate Factor VIII without albumin or vWF (or with relatively low levels of these excipients) have been described. For example, U.S. Patent No. 5,565,427 (EP 508 194) to Freudenberg (assigned to to Beluingwerke) describes Factor VIII preparations which contain particular combinations of detergent and ,amino acids, specifically arginine and glycine, in addition to excipients such as sodium chloride and sucrose. The detergent, polysorbate 20 or polysorbate 80, is descn'bed as being present in amounts of between 0.001 to 0.5% (v/v), while arginine and glycine are present in amounts of between 0.01 to 1:nol/l. Sucrose is descrn'bed as being present in amounts of between 0.1 and 10=0. Example 2 of this patent asserts that solutions of (1) 0.75% sucrose, 0.4 M glycine, and 0.15M NaCI, and (2) 0.01 M sodium citrate, 0.08 M glycine, 0.016M lysine, 0.0025 M calcium chloride, and 0.4 M sodium ~. chloride were not stable in solution over 16 hours, whereas solutions of
(3) 1%
2o sucrose, 0.14 M arginine, 0.1 M sodium chloride and (4) 1% sucrose, 0.4 M
glycine, 0.14 M arginine, 0.1 M sodium chloride, and 0.05% Tween 80 exhibited stability.
U.S. Patent No. 5,763,401 (EP 818 204) to Nayer (assigned to Bayer) also descn'bes a therapeutic Factor VIII formulation without albumin, comprising 15-60 mM sucrose, up to 50 mM NaCI, up to 5 mM calcium chloride, 65-400 mM glycine, and up to 50 mM histidine. The following specific formulations were identified as being stable: (1) 150 mM NaC1, 2.5 mM calcium chloride, and 165 mM mannitol; and (2) 1% sucrose, 30 mM sodium chloride, 2.5 mM
calcium chloride, 20 mM histidine, and 290 mM glycine. A formulation containing higher amounts of sugar (10% maltose, 50 mM NaCI, 2.5 mM
calcium chloride, and 5 mM histidine) was found to exhibit poor stability in the lyophilized state compared with formulation (2).
U.S. Patent No. 5,733,873.(EP 627 924) to Osterberg (assigned to Pharmacia &
Upjohn) discloses formulations which include between 0.01 -1 mg/ml of a surfactant. This patent discloses formulations having the following ranges of excipients: polysorbate 20 or 80 in an amount of at least 0.01 mg/ml, preferably 0.02 - 1.0 mg/ml; at least 0.1 M NaCI; at least 0.5mM calcium salt; and at least 1 mM histidine. More particularly, the following specific formulations are disclosed: (1) 14.7 - 50 - 65 mM histidine, 031- 0.6 M NaCI, 4 mM calcnnn chloride, 0.001 - 0.02 - 0.025% polysorbate 80, with or without 0.1% PEG 4000 or 19.9 mM sucrose; and (2) 20 mg/ml mannitol, 2.67 mg/ml histidine, 18 mgJml NaCI, 3.7 mM calcium chloride, and 0.23 mg/mi polysorbate 80.
, . .
=_ Other attempts to use low or high concentrations of sodium chloride have also been described. U.S. Patent No. 4,877,608 (EP 315 968) to Lee (assigned to Rhone-Poulenc Rorer) teaches formulations with relatively low concentrations 2o of sodium chloride, namely formulations comprising 0.5 mM - 15 mM NaCI, 5 mM calcium chloride, 0.2 mM - 5 mM histidine, 0.01 -10 mM lysine hydrochloride and up to 10% sugar. The "sugar" can be up to 10% maltose, 10 /a sucrose, or 5% mannitol.
US 5,605,884 (EP 0 314 095) to Lee (assigned to Rhone-Poulenc Rorer) teaches the use of formulations with relatively high concentrations of sodium chloride.
These formulations include 0.35 M-1.2 M NaCi,1.5 - 40 mM calcium chloride, 1 mM - 50 mM histidine, and up to 10% of a "sugar" such as mannitol, sucrose,
2o sucrose, 0.14 M arginine, 0.1 M sodium chloride and (4) 1% sucrose, 0.4 M
glycine, 0.14 M arginine, 0.1 M sodium chloride, and 0.05% Tween 80 exhibited stability.
U.S. Patent No. 5,763,401 (EP 818 204) to Nayer (assigned to Bayer) also descn'bes a therapeutic Factor VIII formulation without albumin, comprising 15-60 mM sucrose, up to 50 mM NaCI, up to 5 mM calcium chloride, 65-400 mM glycine, and up to 50 mM histidine. The following specific formulations were identified as being stable: (1) 150 mM NaC1, 2.5 mM calcium chloride, and 165 mM mannitol; and (2) 1% sucrose, 30 mM sodium chloride, 2.5 mM
calcium chloride, 20 mM histidine, and 290 mM glycine. A formulation containing higher amounts of sugar (10% maltose, 50 mM NaCI, 2.5 mM
calcium chloride, and 5 mM histidine) was found to exhibit poor stability in the lyophilized state compared with formulation (2).
U.S. Patent No. 5,733,873.(EP 627 924) to Osterberg (assigned to Pharmacia &
Upjohn) discloses formulations which include between 0.01 -1 mg/ml of a surfactant. This patent discloses formulations having the following ranges of excipients: polysorbate 20 or 80 in an amount of at least 0.01 mg/ml, preferably 0.02 - 1.0 mg/ml; at least 0.1 M NaCI; at least 0.5mM calcium salt; and at least 1 mM histidine. More particularly, the following specific formulations are disclosed: (1) 14.7 - 50 - 65 mM histidine, 031- 0.6 M NaCI, 4 mM calcnnn chloride, 0.001 - 0.02 - 0.025% polysorbate 80, with or without 0.1% PEG 4000 or 19.9 mM sucrose; and (2) 20 mg/ml mannitol, 2.67 mg/ml histidine, 18 mgJml NaCI, 3.7 mM calcium chloride, and 0.23 mg/mi polysorbate 80.
, . .
=_ Other attempts to use low or high concentrations of sodium chloride have also been described. U.S. Patent No. 4,877,608 (EP 315 968) to Lee (assigned to Rhone-Poulenc Rorer) teaches formulations with relatively low concentrations 2o of sodium chloride, namely formulations comprising 0.5 mM - 15 mM NaCI, 5 mM calcium chloride, 0.2 mM - 5 mM histidine, 0.01 -10 mM lysine hydrochloride and up to 10% sugar. The "sugar" can be up to 10% maltose, 10 /a sucrose, or 5% mannitol.
US 5,605,884 (EP 0 314 095) to Lee (assigned to Rhone-Poulenc Rorer) teaches the use of formulations with relatively high concentrations of sodium chloride.
These formulations include 0.35 M-1.2 M NaCi,1.5 - 40 mM calcium chloride, 1 mM - 50 mM histidine, and up to 10% of a "sugar" such as mannitol, sucrose,
4 or maltose. A formulation comprising 0.45 M NaCI, 2.3 mM calcium chloride, and 1.4 mM histidine is exemplified.
International Patent Application WO 96/22107 to Roser (assigned to Quadrant, Holdings Cambridge Limited) describes formulations which include the sugar trehalose. These formulations comprise: (1) 0.1 M NaCI, 15 mM calcium chloride, 15 mM histidine, and 1.27 M(48%) trehalose; or (2) 0.011 % calcium chloride, 0.12% histidine, 0.002% Tris, 0.002% Tween 80,0.004% PEG 3350, 7.5% trehalose, and either 0.13% or 1.03% NaCI.
Other therapeutic Factor VIII formulations of the prior art generaily include albumin andlor vWF for the purpose of stabilizing Factor VIII and are therefore not.relevant to the present invention. For example,-U.S. Patent No. 5,328,694 (EP 511 234) to Schwinn (assigned to Octapharma AG) describes a fonnulation which includes 100 - 650 mM disaccharide and 100 mM- 1.0 M amino acid.
Specifically, the following formulations are disclosed: (1) 0.9 M sucrose, 0.25 '~ .
M glycine, 0.25 M lysine, and 3 mM calcium chloride; and (2) 0.7 M sucrose, 0.5 M giycine, and 5 mM calcium chloride.
While several attempts have been made to formulate Factor VIII without albuniin or vWF, there remains a need for therapeutic Factor VIII formulations which are stable in the absence of albumin or other proteins.
SUMMARY OF THE INVENTION
The present invention relates to therapeutic Factor VIII compositions which are stable in the absence of albumin. In particular, the present invention comprises a Factor VIII composition comprising, in addition to Factor VIII: 4% to 10 %
of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of
International Patent Application WO 96/22107 to Roser (assigned to Quadrant, Holdings Cambridge Limited) describes formulations which include the sugar trehalose. These formulations comprise: (1) 0.1 M NaCI, 15 mM calcium chloride, 15 mM histidine, and 1.27 M(48%) trehalose; or (2) 0.011 % calcium chloride, 0.12% histidine, 0.002% Tris, 0.002% Tween 80,0.004% PEG 3350, 7.5% trehalose, and either 0.13% or 1.03% NaCI.
Other therapeutic Factor VIII formulations of the prior art generaily include albumin andlor vWF for the purpose of stabilizing Factor VIII and are therefore not.relevant to the present invention. For example,-U.S. Patent No. 5,328,694 (EP 511 234) to Schwinn (assigned to Octapharma AG) describes a fonnulation which includes 100 - 650 mM disaccharide and 100 mM- 1.0 M amino acid.
Specifically, the following formulations are disclosed: (1) 0.9 M sucrose, 0.25 '~ .
M glycine, 0.25 M lysine, and 3 mM calcium chloride; and (2) 0.7 M sucrose, 0.5 M giycine, and 5 mM calcium chloride.
While several attempts have been made to formulate Factor VIII without albuniin or vWF, there remains a need for therapeutic Factor VIII formulations which are stable in the absence of albumin or other proteins.
SUMMARY OF THE INVENTION
The present invention relates to therapeutic Factor VIII compositions which are stable in the absence of albumin. In particular, the present invention comprises a Factor VIII composition comprising, in addition to Factor VIII: 4% to 10 %
of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of
5 PCTlUS00/40068 sucrose, trehalose, raffinose, arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCI; and a buffering agent for maintaining a pH of approximately between 6 and S. This composition can additionally comprise a surfactant such as polysorbate 20, polysorbate 80, Pluronic F68, or Brij 35. When the 5 surfactant is polysorbate 80, it should be present in an amount of less than 0.1%.
The buffer of the Factor VIII compositions according to the present invention is preferably present in a concentration of from 10 mM to 50 mM, and is preferably selected from the group consisting of histidine, Tris, BIS-Tris Propane, PIPES, MOPS, HEPES, MES and ACES. Advantageously,. the buffering agent is either histidine or Tris. The Factor VIII composition of the present inven6on can further comprise an antioxidant is The Factor VIII compositions of the preseat invention include both a bulking agent and a stabilizer. The bullcing agent can be present in an amount of from .~ .
about 6% to about 8%, preferably about 8%. The stabilizing agent is preferably present in an amount of about 2%. Sodium chloride is also present in these compositions, preferably in an amount of from 150 to 350 mM, and more 2o preferably in an amount of about 225 mM. The calcium salt of the composition is also preferably calcium chloride, and the composition itself is preferably in lyopluUized form.
In another embodiment, the present invention can comprise a Factor VIII
25 composition formulated without adding albumin which includes the following excipients in addition to Factor VIII: 2% to 6 % hydroxyethyl starch; I% to 4%
of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCI;
and a buffering agent for maintaining a pH of approximately between 6 and 8.
The buffer of the Factor VIII compositions according to the present invention is preferably present in a concentration of from 10 mM to 50 mM, and is preferably selected from the group consisting of histidine, Tris, BIS-Tris Propane, PIPES, MOPS, HEPES, MES and ACES. Advantageously,. the buffering agent is either histidine or Tris. The Factor VIII composition of the present inven6on can further comprise an antioxidant is The Factor VIII compositions of the preseat invention include both a bulking agent and a stabilizer. The bullcing agent can be present in an amount of from .~ .
about 6% to about 8%, preferably about 8%. The stabilizing agent is preferably present in an amount of about 2%. Sodium chloride is also present in these compositions, preferably in an amount of from 150 to 350 mM, and more 2o preferably in an amount of about 225 mM. The calcium salt of the composition is also preferably calcium chloride, and the composition itself is preferably in lyopluUized form.
In another embodiment, the present invention can comprise a Factor VIII
25 composition formulated without adding albumin which includes the following excipients in addition to Factor VIII: 2% to 6 % hydroxyethyl starch; I% to 4%
of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCI;
and a buffering agent for maintaining a pH of approximately between 6 and 8.
6 Preferably, such a composition comprises about 4% hydroxyethyl starch, and the NaCI is present in an amount of 200 mM. The stabilizing agent is also preferably present in an amount of about 2%.
In a further embodiment, the present invention includes a Factor VIiI
composition, formulated without albumin, comprising: 300 mM to 500 mM
NaCI; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffiinose, arginine; x mM to 5 mM calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and 8.
1 o Preferably, the NaCI is present in a concentration of about 400 rnM.
In yet another embodiment, the present invention comprises a proeess for lyophilizing an aqueous Factor VIII composition in a container using a lyophilizer, wherein the prooe.ss comprises an initial freezing step, and the initial is 5eezing step fiuther comprises the steps ot (a) lowering the temperature of the lyophilizer chamber to at least about -05 C; (b) raising the temperature of the chamber to between about -15 C and -25 C; and subsequently (c) lowering the temperature of the chamber to at least about -45 C. In this process, the temperature of the chamber is preferably lowered or raised at a rate of betweea 2o about 0.5 C and about 1.0 C per minute. In step (a), the temperature is preferably maintained for about 1 hour, and is lowered to about -55 C. In step (b) the temperature is preferably maintained be -15 C and -25 C for between I
and 3 hours, and more preferably is at -22 C, and the temperature in step (c) is preferably maintained for about 1 hour. The Factor VIII composition used in 25 this process preferably comprises between 4% and 10'/0 of an agent selected from the group consisting of mannitol, glycine and alanine, and also prefenibly comprises between 1% and 4% of an agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine. In addition, the Factor VIII
In a further embodiment, the present invention includes a Factor VIiI
composition, formulated without albumin, comprising: 300 mM to 500 mM
NaCI; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffiinose, arginine; x mM to 5 mM calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and 8.
1 o Preferably, the NaCI is present in a concentration of about 400 rnM.
In yet another embodiment, the present invention comprises a proeess for lyophilizing an aqueous Factor VIII composition in a container using a lyophilizer, wherein the prooe.ss comprises an initial freezing step, and the initial is 5eezing step fiuther comprises the steps ot (a) lowering the temperature of the lyophilizer chamber to at least about -05 C; (b) raising the temperature of the chamber to between about -15 C and -25 C; and subsequently (c) lowering the temperature of the chamber to at least about -45 C. In this process, the temperature of the chamber is preferably lowered or raised at a rate of betweea 2o about 0.5 C and about 1.0 C per minute. In step (a), the temperature is preferably maintained for about 1 hour, and is lowered to about -55 C. In step (b) the temperature is preferably maintained be -15 C and -25 C for between I
and 3 hours, and more preferably is at -22 C, and the temperature in step (c) is preferably maintained for about 1 hour. The Factor VIII composition used in 25 this process preferably comprises between 4% and 10'/0 of an agent selected from the group consisting of mannitol, glycine and alanine, and also prefenibly comprises between 1% and 4% of an agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine. In addition, the Factor VIII
7 composition used in this process also preferably comprises between 100 mM and 300 mM NaCI.
In accordance with an aspect of the present invention, there is provided a Factor VIII composition formulated without adding albumin to said composition, compri sing the following fonnulation excipients in addition to Factor VIII:
mM to 500 mM NaC1; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; i mM to 5 mM
calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and
In accordance with an aspect of the present invention, there is provided a Factor VIII composition formulated without adding albumin to said composition, compri sing the following fonnulation excipients in addition to Factor VIII:
mM to 500 mM NaC1; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; i mM to 5 mM
calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and
8.
DETAILED DESCRIPTION OF THE INVENTION
Definitions As used herein, the terms below and variations thereof shall be defined as follows, unless otherwise indicated:
Factor VIII - The Factor VIII molecule exists naturally and in therapeutic preparations as a heterogeneous distribution of polypeptides arising from a single gene product (see, e.g., Anderson et al., Proc. Natl. Acad. Sci. USA, 83, 2979-2983, May 1986). The term "Factor VIII" as used herein refers to all such polypeptides, whether derived from blood plasma or produced through the use of recombinant DNA techniques. Commercially available examples of therapeutic preparations containing Factor VIII include those sold under the trade names of HEMOFIL M and RECOMBINATE (available from Baxter Healthcare Corporation, Deerfield, Illinois, U.S.A.). Other preparations currently in development comprise primarily a single subpopulation of Factor VIII molecules which lack the B domain portion of the molecule.
7a International Unit, IU- International Unit, or IU, is a unit of measurement of the blood coagulation activity (potency) of Factor VIII as measured by a standard assay, such as one of the following:
One stage assay. One stage assays are known to the art, such as that described in Lee, Martin L, et al., An Effect of Predilution on Potency Assays of Factor VIII Concentrates, Thrombosis Research (Pergamon Press Ltd.) 30, 511-519 (1983).
.CA 02634674 2008-07-10 s ChromoLyenic assay. Chromogenic assays may be purchased commerciaIIy, such as the Coatest Factor VIII, available from Chromogenix AB, Molndal, Sweden.
Anneal The term anneal shali be used to indicate. a step in the lyophilization process of a phannaceutical preparation undergoing lyophilization, prior to the freeze-drying of the preparation, in which the temperature of the pr"ration is raised from a lower temperature to a higher temperature and then cooW again aftar a period of time.
BulkingAgent For the purposes of this application, bulking agents are those chemical entities which provide structnrc to the "cake" or residual solid mass of a pharmaceutical preparation a8er it ltas been lyopln7ized and which protect it against collapse. A crystallizable.bulldng agent shall mesa a bulking agent as descn'bed barein which can be crystallized during lyophilization, other than sodium chloride: HES is,not included in this group of crystallizable bullang agents.
Freeze-drying, f'ieezing, lyophillzing-"Fraoze-drying," uniess otherwise indicated by the context in which it appears, sball be used to denote the po=tion of a lyophilization process in which the temperatlue of a pharmaceutical . . ) preparation is raised in order to drive water out of the preparation'. The "freezing" steps of a lyophflization process are those steps whieh occur prior to ihe freeze-drying stage. "2,yophilizing," unless otherwise indicated, shall rafer- .
to the entire process of lyophilization, including both the breezing steps and the freeze-drying steps.
Unless -otherwise noted, pem.eatage terms express weight/volume percentages and temperatures are in the Celsius scale.
DETAILED DESCRIPTION OF THE INVENTION
Definitions As used herein, the terms below and variations thereof shall be defined as follows, unless otherwise indicated:
Factor VIII - The Factor VIII molecule exists naturally and in therapeutic preparations as a heterogeneous distribution of polypeptides arising from a single gene product (see, e.g., Anderson et al., Proc. Natl. Acad. Sci. USA, 83, 2979-2983, May 1986). The term "Factor VIII" as used herein refers to all such polypeptides, whether derived from blood plasma or produced through the use of recombinant DNA techniques. Commercially available examples of therapeutic preparations containing Factor VIII include those sold under the trade names of HEMOFIL M and RECOMBINATE (available from Baxter Healthcare Corporation, Deerfield, Illinois, U.S.A.). Other preparations currently in development comprise primarily a single subpopulation of Factor VIII molecules which lack the B domain portion of the molecule.
7a International Unit, IU- International Unit, or IU, is a unit of measurement of the blood coagulation activity (potency) of Factor VIII as measured by a standard assay, such as one of the following:
One stage assay. One stage assays are known to the art, such as that described in Lee, Martin L, et al., An Effect of Predilution on Potency Assays of Factor VIII Concentrates, Thrombosis Research (Pergamon Press Ltd.) 30, 511-519 (1983).
.CA 02634674 2008-07-10 s ChromoLyenic assay. Chromogenic assays may be purchased commerciaIIy, such as the Coatest Factor VIII, available from Chromogenix AB, Molndal, Sweden.
Anneal The term anneal shali be used to indicate. a step in the lyophilization process of a phannaceutical preparation undergoing lyophilization, prior to the freeze-drying of the preparation, in which the temperature of the pr"ration is raised from a lower temperature to a higher temperature and then cooW again aftar a period of time.
BulkingAgent For the purposes of this application, bulking agents are those chemical entities which provide structnrc to the "cake" or residual solid mass of a pharmaceutical preparation a8er it ltas been lyopln7ized and which protect it against collapse. A crystallizable.bulldng agent shall mesa a bulking agent as descn'bed barein which can be crystallized during lyophilization, other than sodium chloride: HES is,not included in this group of crystallizable bullang agents.
Freeze-drying, f'ieezing, lyophillzing-"Fraoze-drying," uniess otherwise indicated by the context in which it appears, sball be used to denote the po=tion of a lyophilization process in which the temperatlue of a pharmaceutical . . ) preparation is raised in order to drive water out of the preparation'. The "freezing" steps of a lyophflization process are those steps whieh occur prior to ihe freeze-drying stage. "2,yophilizing," unless otherwise indicated, shall rafer- .
to the entire process of lyophilization, including both the breezing steps and the freeze-drying steps.
Unless -otherwise noted, pem.eatage terms express weight/volume percentages and temperatures are in the Celsius scale.
9 Formulation Components The Factor VIII compositions of the present invention include bulking agents, stabilizing agents, buffering agents, sodium ~chloride, calcium salts, and, advantageously, other excipients. = These excipients have been chosen in order to maximize the stability of Factor VIII in lyophilized preparations.. However, the Factor VII1 compositions of the present invention exhibit stability in the liquid state as well.
lo The bulking agents used in the pmsent formulations, which form the crystalline portion of the lyophilized product (except in the case of HES), are selected from the group consisting of mannitol, glycine, alanine, and hydroxyethyl sfiar+ch (HES). Mannitol, glycine, or alanine are present in an amount of 4 - 10%, preferably 6- 9'/o, and more preferably about 8%. When HES is used as a bulking agent, it is present in an amouat of 2 - 6%, preferably 3- 5'/0, and more preferably about 4%.
=, The stabilizing agents used in the formulations of the present invention are selected from the group consisting of sucrose, trehalose, raffinose, and arginine.
2o These agents are present in the formulations of the present invention in an amount of between 1- 4%, preferably 2- 3%, more preferably about 2%.
Sorbitol and glycerol were evaluated as possible stabilizrrs but were found to be poor stabilizers in the present formulations.
Sodium chloride is included in the present formulations in an amount of 100 -300 mM, preferably 150 - 250 mM, and most preferrably about 225 mM. In one embodiment of the present invention, sodium chloride itself can be used without any of the aforementioned bulking agents, in which case it would be included in the formulation in an amount of between 300 mM and 500 mM NaCI, preferably 350 to 450 mM NaCI, and more preferably about 400 mM NaCI.
In addition, buffers are present in these formulations, because it is believed that s the Factor VIII molecule can be adversely affected by pH shifts during lyophilization. The pH should preferably be maintained in the range of between 6 and 8 during lyophilization, and more preferably at a pH of about 7. The buffering agent can be any physiologically acceptable chemical entity or combination of chemical entities which have the capacity to act as buffers,
lo The bulking agents used in the pmsent formulations, which form the crystalline portion of the lyophilized product (except in the case of HES), are selected from the group consisting of mannitol, glycine, alanine, and hydroxyethyl sfiar+ch (HES). Mannitol, glycine, or alanine are present in an amount of 4 - 10%, preferably 6- 9'/o, and more preferably about 8%. When HES is used as a bulking agent, it is present in an amouat of 2 - 6%, preferably 3- 5'/0, and more preferably about 4%.
=, The stabilizing agents used in the formulations of the present invention are selected from the group consisting of sucrose, trehalose, raffinose, and arginine.
2o These agents are present in the formulations of the present invention in an amount of between 1- 4%, preferably 2- 3%, more preferably about 2%.
Sorbitol and glycerol were evaluated as possible stabilizrrs but were found to be poor stabilizers in the present formulations.
Sodium chloride is included in the present formulations in an amount of 100 -300 mM, preferably 150 - 250 mM, and most preferrably about 225 mM. In one embodiment of the present invention, sodium chloride itself can be used without any of the aforementioned bulking agents, in which case it would be included in the formulation in an amount of between 300 mM and 500 mM NaCI, preferably 350 to 450 mM NaCI, and more preferably about 400 mM NaCI.
In addition, buffers are present in these formulations, because it is believed that s the Factor VIII molecule can be adversely affected by pH shifts during lyophilization. The pH should preferably be maintained in the range of between 6 and 8 during lyophilization, and more preferably at a pH of about 7. The buffering agent can be any physiologically acceptable chemical entity or combination of chemical entities which have the capacity to act as buffers,
10 including histidine, Tris, BIS-Tris Propane, PIPES, MOPS, HEPES, MFS and ACES. The full chemical designations of these buffering agents is listed in Table I below. Typically, the buffering agent is included in a concentration of 10 - 50 mM. When histidine is added to the formulations, concentrations of over 20 mM and preferably about 25 mM are used, alone or in combination with is other buffers such as Tris. Histidine is especially preferred for use in the compositions of the present invention, as descrn'bed in greater detail below.
A . _ Table I - Buffering Agents Tris tris{hydroxymethyl)-aminomethane BIS-Tris Propane 1,3-bis-[tris-(hydroxy-methyl)methylamino]-propane.
PIPES piperazine NMbis-p-ethanesulfonic acid) MOPS 3-{N morpholino) propanesulfonic acid HEPES N-2-hydroxyethyl-piperazine N 2-ethanesulfonic acid MF.S 2-(N-morpholino) ethanesulfonic acid ACES N-2-acetamido-2-aminoethanesulfonic acid 2o In. order to preserve the activity of Factor VIII, it is important that the formulations of the present invention also include calcium or another divalent cation able to interact with Factor VIII and maintain its activity, presumably by
A . _ Table I - Buffering Agents Tris tris{hydroxymethyl)-aminomethane BIS-Tris Propane 1,3-bis-[tris-(hydroxy-methyl)methylamino]-propane.
PIPES piperazine NMbis-p-ethanesulfonic acid) MOPS 3-{N morpholino) propanesulfonic acid HEPES N-2-hydroxyethyl-piperazine N 2-ethanesulfonic acid MF.S 2-(N-morpholino) ethanesulfonic acid ACES N-2-acetamido-2-aminoethanesulfonic acid 2o In. order to preserve the activity of Factor VIII, it is important that the formulations of the present invention also include calcium or another divalent cation able to interact with Factor VIII and maintain its activity, presumably by
11 maintaining the association of the heavy and light chains of Factor VIII.
Between I mM and 5 mM of a calcium salt can be used, more preferably 3- 4 mM, and most preferably about 4 mM. The calcium salt is preferably ca]cium chloride, but can also be other calcium salts such as calcium gluconate, calcium glubionate, or calcium gluceptate.
The Factor VIII compositions of the present invention also preferably include a surfactant, preferably in an amount of 0.1 % or less, and more preferably in an amount of about 0.03%. The surfactant can, for example, be chosen from the t o group consisting of polysorbate 20, polysorbate 80, pluronic polyols, and Brij 35 (polyoxyethylene 23 lauryl ether). Several grades of pluronic polyols (sold under the trade name Pluronic, manufactured by the BASF Wyandotte Corporation) are available. These polyols, of diversified molecular weight (from 1,000 to over 16,000) and physicochemical properties have been used as ts surfactants. Pluronic F-38, of a molecular weight of 5,000 and Pluronic F-68, molecular weight 9,000, both contain (by weight) 80 per cent hydrophilic polyoxyethylene groups and 20 percent hydrophobic.polyoxypropylene groups.
Tween-80, a comniercial polysorbate, however, is preferred in the present fonnulations, in particular vegetable-derived Tween-80.
The Factor VIII formulations of the present invention also preferably include an antioxidant. The addition of antioxidants to the lyophilized formulations of the invention has been found to improve the stability of these fonnulations, and thus extend their shelf lives. The antioxidants used must be compatible for use with a pharmaceutical preparation, and in addition are preferably water soluble.
When adding antioxidants to a formulation, it is preferable to add such antioxidants as late in the process prior to lyophilization as possible, in order to avoid spontaneous oxidation of the antioxidant. Table 2 below lists suitable
Between I mM and 5 mM of a calcium salt can be used, more preferably 3- 4 mM, and most preferably about 4 mM. The calcium salt is preferably ca]cium chloride, but can also be other calcium salts such as calcium gluconate, calcium glubionate, or calcium gluceptate.
The Factor VIII compositions of the present invention also preferably include a surfactant, preferably in an amount of 0.1 % or less, and more preferably in an amount of about 0.03%. The surfactant can, for example, be chosen from the t o group consisting of polysorbate 20, polysorbate 80, pluronic polyols, and Brij 35 (polyoxyethylene 23 lauryl ether). Several grades of pluronic polyols (sold under the trade name Pluronic, manufactured by the BASF Wyandotte Corporation) are available. These polyols, of diversified molecular weight (from 1,000 to over 16,000) and physicochemical properties have been used as ts surfactants. Pluronic F-38, of a molecular weight of 5,000 and Pluronic F-68, molecular weight 9,000, both contain (by weight) 80 per cent hydrophilic polyoxyethylene groups and 20 percent hydrophobic.polyoxypropylene groups.
Tween-80, a comniercial polysorbate, however, is preferred in the present fonnulations, in particular vegetable-derived Tween-80.
The Factor VIII formulations of the present invention also preferably include an antioxidant. The addition of antioxidants to the lyophilized formulations of the invention has been found to improve the stability of these fonnulations, and thus extend their shelf lives. The antioxidants used must be compatible for use with a pharmaceutical preparation, and in addition are preferably water soluble.
When adding antioxidants to a formulation, it is preferable to add such antioxidants as late in the process prior to lyophilization as possible, in order to avoid spontaneous oxidation of the antioxidant. Table 2 below lists suitable
12 antioxidants, which are available commercially through companies sqch as Calbiochem and Sigma.
Table 2 - Antioxidants N-Acetyl-L-Cysteine / Homocysteine Glutathione 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) Lipoic acid Methionine Sodium Thiosulfate Platinum Glycine-glycine-histidine (tripeptide) Butylatedbydroxytoluene (BHT) Of the foregoing antioxidants, glutathione is preferred. Concentrations in the range of about 0.05 mg/ml to more than 1.0 mg/ml have all been found to enhance the stability of Factor VIII compositions, and it is believed that higher concentrations would also be useful (up to the point of any toxic effects or l0 adverse manufacturing effects, such as a depression of the glass bmisition temperature of the lyophilized product).
It has been found in particnlar that the c.otnbination of histidine and giutathione produces synergistically beneficial effects on the stability of Factor V1II
compositions. Histidine, while acting as a buffer, can also act as a metal chelator. To the extent that Factor VIII inactivation is caused by metal-induced oxidation, histidinb can therefore act to stab'lize Factor VIII by binding such oxidizing metal ions. It is believed that by binding these metals, the ghitathione (or indeed any other antioxidant present) is thereby able to provide further
Table 2 - Antioxidants N-Acetyl-L-Cysteine / Homocysteine Glutathione 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) Lipoic acid Methionine Sodium Thiosulfate Platinum Glycine-glycine-histidine (tripeptide) Butylatedbydroxytoluene (BHT) Of the foregoing antioxidants, glutathione is preferred. Concentrations in the range of about 0.05 mg/ml to more than 1.0 mg/ml have all been found to enhance the stability of Factor VIII compositions, and it is believed that higher concentrations would also be useful (up to the point of any toxic effects or l0 adverse manufacturing effects, such as a depression of the glass bmisition temperature of the lyophilized product).
It has been found in particnlar that the c.otnbination of histidine and giutathione produces synergistically beneficial effects on the stability of Factor V1II
compositions. Histidine, while acting as a buffer, can also act as a metal chelator. To the extent that Factor VIII inactivation is caused by metal-induced oxidation, histidinb can therefore act to stab'lize Factor VIII by binding such oxidizing metal ions. It is believed that by binding these metals, the ghitathione (or indeed any other antioxidant present) is thereby able to provide further
13 antioxidative protection, since the oxidative effect of the metal ions bound by.
the histidine has been contained.
Other chelating agents might also be used in the compositions of the present invention. Such agents should preferably bind metals such as copper and iron with greater afI'inity than -calcium, if a calcium salt is being used in the composition. One such chelator is deferoxamine, a chelating agent that facilitates the removal of Al++ and iron. Deferoxamine Mesylate, C25H48N608*CH4O3S, can be obtained from Sigma (Sigma Prod. No.
D9533). It is an aluminum and iron(II) chelator which chelates iron (as a 1:1 chelate complex) only in the +3 oxidation state, not. +2 oxidation state, and can also bind manganese ion and other metals. Deferoxamine can be used advantageously in an amount of 0.25 mg/1.
The Factor VIII used in the present formulations can be either highly purified human pl.asma-derived Factor VIII or more preferably can be recombinantly ;= produced Factor VIII. Recombinant Factor VIII can be produced by Chinese hamster ovary (CHO) cxils transfected with a vector canying a DNA sequenee coding for the Factor VIII molecule. Methods for creating such transfected CI>YO
2o cells are described, inter alia, in U.S. Patent No. 4,757,006 to Toole, Jr., though altemative methods are also lcnown to the art (see, e.g., U.S. Patent No.
4,868,112, also to Toole, Jr., and PCT Intemational Application WO-A-91/09122). The methods used to culture such CHO cells to produce Factor VIII
are also known to the art, for example in European Patent Application No. 0 25- 218 to Genetics Institute, entitled "Improved method for producing Factor VIII:C-type proteins." " Recombinant Factor ViII can, however, also be produced in other cell lines, such as baby hamster lddney (BHK) cells. The Factor ViII
molecule itself, if recombinantly produced, can be either full-length Factor VIII
Wo 00/48635 PCT/US00/4006s
the histidine has been contained.
Other chelating agents might also be used in the compositions of the present invention. Such agents should preferably bind metals such as copper and iron with greater afI'inity than -calcium, if a calcium salt is being used in the composition. One such chelator is deferoxamine, a chelating agent that facilitates the removal of Al++ and iron. Deferoxamine Mesylate, C25H48N608*CH4O3S, can be obtained from Sigma (Sigma Prod. No.
D9533). It is an aluminum and iron(II) chelator which chelates iron (as a 1:1 chelate complex) only in the +3 oxidation state, not. +2 oxidation state, and can also bind manganese ion and other metals. Deferoxamine can be used advantageously in an amount of 0.25 mg/1.
The Factor VIII used in the present formulations can be either highly purified human pl.asma-derived Factor VIII or more preferably can be recombinantly ;= produced Factor VIII. Recombinant Factor VIII can be produced by Chinese hamster ovary (CHO) cxils transfected with a vector canying a DNA sequenee coding for the Factor VIII molecule. Methods for creating such transfected CI>YO
2o cells are described, inter alia, in U.S. Patent No. 4,757,006 to Toole, Jr., though altemative methods are also lcnown to the art (see, e.g., U.S. Patent No.
4,868,112, also to Toole, Jr., and PCT Intemational Application WO-A-91/09122). The methods used to culture such CHO cells to produce Factor VIII
are also known to the art, for example in European Patent Application No. 0 25- 218 to Genetics Institute, entitled "Improved method for producing Factor VIII:C-type proteins." " Recombinant Factor ViII can, however, also be produced in other cell lines, such as baby hamster lddney (BHK) cells. The Factor ViII
molecule itself, if recombinantly produced, can be either full-length Factor VIII
Wo 00/48635 PCT/US00/4006s
14 or a deletion derivative ahereof, such as a B domain-deleted Factor VIII
molecule.
While the Factor VIII compositions descnbod in this application can be s lyophilized and reconstituted in the indicated concentrations, one of skill in the art wiil undecstand that these preparations can also be reconstituted in more dilute form. FoT example, a praparation according the present invention which is lyopbilized and/or normally reconstituted in 2 ml of solution can also be reconstituted in a larger volume of diluent, such as 5 ml. This is particulariy t o appropriate when the Factor VIII preparation is being injected into a patient immediately, since in this can the Factor VIII is less likely to lose activity, ti which may occur more rapidly in more dilute solutions of Factor VIII.
Formulation and Lyophilization Development is In order to achieve maximal stability, the Factor VIII compositions of the present invention are preferably Iyophiliaed. During lyophiization, Factor VIII
A =
= . ~ . ~ is converted from being in an aqueous phase to being in an amorphous solid phase, which is thought to protect the protein from chemical and/or conformational instability. The lyophilized preparation not only contains an 26 amorphous phase, but also includes a component which crystallizes during lyophilization. This is thought to allow the rapid lyophilization of the Factor ) VIII composition and the formation.of a mqre elegant cake (that is, a cake with minimal shrinkage from the sides of the container in which it was lyophiiized).
In the formulations of the present invention, the stabilizing agents have been 25 selected to exist primarily in an amorphous phase of the lyophilizel product, while the bulking agents (except HES) have been selected to crystallize during freezing.
WO 00148635 pCT/t1S00/40068 Both the Factor VIiI and the stabilizer are preferably dispersed in the amorphous phase of the lyophiliwd cake. The mass of the stabilizer is also preferably large compared to the o8ier excipients in the amorphous form. In addition, the apparent glass transition temperature (T,,') of the amorphous phase 5 is preferably relatively high during freeze-drying, and the glass transition temperature (Tg) of the solid is likewise preferably high during storage.
Crystallization of sodium chloride in the product was found to be desirable, since amorphous sodium chloride will depress the T.' of the amorphous phase.
10 In order to avoid the collapse of the cake of a particular composition, primary drying is preferably carried out at a product temperature bedow. the apparent glass transition temperature of the fceeze concentrate. An increase in drying time may also be required to offset a decrease in Ts . Further information on lyophilization may be found in Carpenter, J.F. and Chang, B.S., Lyophilization is ofProtein Pharmaceuticals, Biotechnology and Biophannaceutical Manufacturin8, Processing and Preservation, K.E. Avis and V.L. Wu, eds.
~ . =
(Buffalo Grove, IL: Interpharm Press, Inc.), pp. 199-264 (1996).
Example 1 2o The effects of the concentration of Factor VIII and of the addition of a stabilim on the recovery of Factor VIII were investigated in several studies. These studies were performed using mannitol as a model bulking agent and sucrose as a model stabilizer. The three sample formulations descn'bed in Table 3 below were used in these studies. AU formulations used in these studies included 10 - mM Tris, 200 mM NaC1, 8% mannitol, 4 mM CaC12; and 0.02% Tween-80 and were conducted at pH 7Ø
WO 00148635 PC7'/USOO/40068 IG
Table 3 Sample Initial Factor VIII Sucrose %
I.D. (IU/ml) These samples were lyophilized using the fieer.e-drying cycle shown in Table 4 below in order to maintain a product temperature below the apparent glass transition temperature (T..'). Differential scanning calorimetric (DSC) studies indicated the presence of a trnnsition at approximately -40 C in the mannitol formulations. In order to maintain a product temperature below this value, the shelf temperature was set to -32 C during primary drying. Primary drying under these conditions was perfonned for about 55 hours, with a total cycle time of about 80 hours.
WO 00/48635 PCT/i)S00/40068 Table 4 Freezing/Processing Description Method I Cool to +5 C;
(Freezing) Cool to -5 C at 1 C/minute, hold for 20 minutes;
Cool to 20 + 5 C at I C/niinute; hold for 1 hour (up to 3 hours);
Cool to -45 C at 0.5 C/minute, hold for 1 hour.
II Freeze per method I
Hold at 35 C for 48 hours.
~ Freeze per method I
Hold at -35 C for 48 hours;
Hold at 20 C for 48 hours.
IV Shelf -32 C during primaiy drying for (Freeze-drying) about 55 hours (up to 100 hours);
Product < -40 C durin8 pnnar'y drying:
Ramp fratn -32 C to +40 C at 0.2 Gminute;
Shelf +40 C during secondary drying for 3 hours.
The Factor VIII activity of these samples, as determined by the one-stage clotting assay, was compared against a control held at -45 C. The assay results are shown in Table 5 below.
Table 5 Processing % Loss in Factor. VIII Activity During Each Step Method Formulation IA Formulation IB Formulation IC
(600 IUhn1) (60 IIJ/ml) (60 IU/ml, 2%
Sucrose) I 6.7 37.5 41.7 II 2.0 9.3 3.9 III 7.3 11.6 5.0 IV 20.0 24.2 18.3 (Lyophilization) These results indicate that protein concentration has an effect on the recovery of .
Factor VIII during freezing. Formulations containing 60 IU/mi lost approximately 37 /.-42% of the initial Factor VIII activity duriag the frcezing step, while 6.7% of Factor VIII activity was lost for the formulation containiag 600 IU/ml. These results indicate that a higher protein concentration has a protective effect during freezing. Although sucrose provided some protection to the Factor VIII duzing tho intermediate tempera'ture holds as well as during freeze-drying, it failed to protect the protein during the initial freezing step.
Ezamaie 2 Following the development of the lyophilization process outlined in Example 1, fiuther optimization of this process was undertalcen. It has been found that a lyophilized composition having a higher giass transition teanperature, (and, theoretically, better Factor VIII stability) can be produced by: (1) lowering the freezing temperature initially to -45 C or lower (such as down to about -50 C
or -55 C); (2) raising the temperature to -20 C or -22 C (+5 C); and then (3) lowering the temperature again to 45 C or lower. The temperature is lowered or raised, as the case may be, at a rate of between about 0.5 C and about 1.0 C
per minute. Once the desired temperature is reached, the composition is held at that temperature for betweea I and 3 hours. This improved freezing cycle is shown in Table 6 below.
Table 6 Freezing Method Description I Cool to +5 C;
Cool to -5 C at 0.5-1 C/minute, hold for 20 n2inntes;
Cool to between-55 C and 45 C at 0.5-1 C/minute, hold for about 1 hour, Warm to 22 C ( 5 C) at 0.5-1 Cfminute, hold for I to 3 hours;
Cool to -45 C at 0.5-1 Clminute, hold for about 1 hour.
=, .
' 10 Unless otherwise indicated, the temperatures referred to in this example and in other examples refer to the shelf tcmpGrature of the lyophilizer and not to the temperature of the product per se. Following the improved fiwzing cycle, the remainder of the lyophilization process can be conducted as outlined in Example I above, or otherwise as descn'bed fnrther herein or as determined by one of sidll in the art.
This improved lyophilization procxss was found to be useful for formulations which include glycine as the bulking agent as we11 as those which use mannitol.
It is fn:ther beiieved to have applicability to formulations which make use of the other bulkiing agents of the present invention as well.
Example 3 It is believed that in order to produce a freem-dried product with acceptable cake appearance and glass transition temperature, the bulking agent of lyophilized pharmaceutical preparations which contain sodium chloride, such as 5 glycine or mannitol, may need to be crystallized. The following improved lyophilization process for crystallizable bulldn.g agents was therefore developed Table 7a - Freezing Steps Process Step Temperature Duration of Step Initial fireezing -40 C or less 1 hour First annealing between 23 C and 27 C 3 hours Second freezing -55 C 1 hour Second annealing -36 C 4 hours Third fieezing -50 C 1 hour Table 7b - Freeze-Drying Steps Process Step Temperature Duration of Step Primary Drying -35 C up to 100 hours Secondary Drying: First step 40 C 3 hours Secondary Drying: Second step 45 C 3 hours Secondary Drying: Tbird step 50 C 3 hours In the freezing steps, changes in the temperatures occurred at a rate of between about 0.5 C/minute and 1 C/minute. It is believed that steps of longer duration would also be effective.
Prior to the first freezing step, the temperature is brought to between about and 8 C for about one hour for the purpose of bringing all the vials to approximately the same temperature. After this the lyophilizer is cooled to -C. The first free2ing step should be performed at a temperature less than -s 30 C, preferably below 35 C, and more preferably at about -40 C: Following this, the first annealing step should occur at a temperature of between -30 C
and -19 C, more preferably either between about 25 C and -28 C (if glycine is the bulking agent) or between 21 C and 24 C (if numnitol is the bulking agent), with the temperatures of 23 C and 26 C being most preferred, at which 1 o temperatures it is believed that the ciystallizable bullcing agents crystallize, at least in part. However, the lower range around 27 C is not recommended for formulations containing mannitol and arginine. This step is preferably carried out for about 3 hours.
13 Following the first annealing step, the temperature is lowered, preferably to kss than about 50 C and more preferably to less than 55 C, for about 1 hour. It is ~.. -. believed that the sodium chloride in the preparation nucleates at this time.
During the second annealing step, the temperature of the pharmaceutical 2o preparation is raised to between about 30 C and ,39 C, and preferably to about -33 C for mannitol-containing compositions and -36 C for glycine-containing compositions. It is believed that AlaCl crystal growth occurs at this time, at least in part. This step is preferably conducted for about 4 hours. Following this, the temperature of the lyophilizer is reduced to about -SO C, preferably for about 25 hour in order to reduoe the temperature of the preparation.
In the freeze-drying steps which follow, changes in temperature occurred at a rate of between about 0.1 C/minute and o.S C/minute. After reducing the pressure in the lyophilizer to about 65 mTorr, the temperature is raised to between about -32 C and -35 C for primary drying. Ice crystals in the preparation will sublimate at this temperature. This step is performed for up to about 100 hours, or until most of the ice has been sublimated fiom the preparation. The point at which most of the ice has sublimated can be detecmined, for example, using a dewpoint sensor, which indicates the end of the sublimation of ice when the readings decrease (the point of inflection).
Following primary drying, the temperature is raised to +40 C, preferably at a rate of 0.2 C/minute, to initiate secondary drying to remove further water from the preparation. This temperature is preferably maintained for about three hours. Second and third secondary dtying steps follow this first step, where the temperature is raised to about +45 C for about three hours and then to about +50 C for three more hours in order to reduce the moisture in the lyophilized cake to less than 2% (w/w).
Example 4 ~:::= Further studies were performed to examine specifically the effect of histidine on lyophilized Factor VIII compositions containing glycine or snannitol as bullcing agents. Non-reversing heat flow (Modulated DSC, mDSC) was used to detect the crystallization of these bulldng agents during cooling. Both the temperature of crystallization and the total heat of crystallization were determined from the crystallization exotherm. The appearance of the NaCI eutectic melt endotherm during warming was used to detect NaCI 'crystall.ization. In mDSC, the extent of crystallization was detennined as the ratio of the enthalpy of melting of the formulation to the enthalpy of inelting of pure NaCI solution by using the total heat flow signal. In addition, X-ray diirraction analyses were performed in order to determine the extent of crystallization in the lyophilized formulations.
While histidine concentrations less than 20 mM did not significantly impaet the crystallization of glycine, 50 mM histidine reduced the extent of glycine crystallization. Well-defined NaCI crystallization exotherms were not observed during cooling of fonnulations containing glycine. However, cutectic melting endotherms during heating indicated that NaCI was crystallized (> 50%) after cooling lower than -50 C and annealing at _ 30 C, -35 C and -40 C. The inclusion of 50 mM histidine in the glycine-oontaining formulation retarded NaCI crystallization. Consequently, the annealing time was increased 3-fold for such fonnulations in order to achieve an equivalent crystallinity.
However, the effect of 20 mM histidine on the crystallization of NaCI in the glycine-containing fomnulations was minimal. In fiuze-drying studies, collapse of the lyophilized cake was observed visually in glycine-containing formulations containing 50 mM histidine. X-ray powder diflicaction data indicated a decrease in the crystallinity of NaCI in samples containing histidine.
In mannitnl-containing formulations, typically 83% - 90% of the sodium chloride crystallized during cooling betweea -40 C and 50 C without the need for annealing. While inclusion of 20 mM histidine to the formulation suppressed NaC1 crystallization during cooling, annealing resulted in approximately 40% crystallization of the NaCI.
Tberefore, in formulations containing a crystallizable bulking agent, such as glycine or mannitol, and NaCI, the inclusion of histidine may decrease the extent of crystalliution of NaCl. tllthough this could in some cases lead to the - collapse of the cake which is formed during lyophdization, the use of relatively lower concentrations of histidine in such fomaulations.can mitigate this effect.
Nonetheless, acceptable cakes have been fonned with concentrations of histidine of 35 mM and 50 mM. Histidine may also be preferable to FI;EPHS as a buffer in mannitol- and glycine-based formulations, as the use of HERIrS.
has been observed to lower the Tg' to a greater extent than a similar amount of histidine.
Example 5 The physical characteristics of a number of potential Factor VIII
formulafions, including seven candidate stabilizers and five bulking agents, were evaluated in another stndy. In addition to a bulking agent and stabilizer, all formulations listed in Table 8 below (except for formulation 11) contained 10 mM Tris=HC1, 200 mM NaC1, 0.02'/o Tween-80, 4 mM CaC12 and were at pH 7Ø Formulation 11 contained 10 mM Tris*HCl, 0.02% Tween-80, and 4 mM CaCl2, also at pH
7Ø All pH measurements were performed at ambient temperature.
Table 8 Sample Buiking Agent Protein I D. Stabilizer 1 80/0 Mannito] 2% Sucrose 2 8% Mannitol 2% TreWose 3 8% Mannitol 2% Raffinose 4 8'/o Mannitol 2% Arginine 5 8% Mannitol 2% Lysine 6 8% Mantritol 2% Sorbitol 7 8% Mamutol r/o Glycxrol 8 4% Hydroxyethyl 2% Sumse Starch 9 8% Glycine 2% Sucrose .~ , ~ ' .'. == = ' 10 8% Glycine . 2% Trehalose , 11 400 mM NaCI 20/o Sucrose 12 8% Alanine 2% Sucwse Collapse temperature mcasuremeats by freeze-dry microscopy and thermal S transition measurements by DSC were used to predict fleme-drying behavior.
DSC, X-ray powder diffiaction and polarized light microseopy were also used to determine the crystallinity of the lyophilized sampks. The reconstitution time and the appearance of the samples were aLso evaluated. The results of all of these measuretnents are summarized in Table 9 below.
Table 9 Sample TV. T, Ts Reconstitution Water LD. ( C) ( C) ( C) (seconds) Conteat APpearance 1 -14 -10 54 64 n/c Elegant 2 -20 -15 53 62 1.4 Top partially collapsed 3 -15 -10 54 77 1.7 Elegant 4 - - - - - Partial collapse - - - - Collapsed 6 n/c n/c < 10 C' 63 0.6 Elegant 7 < 10 C' - - Elegant 8 - - 86 49 0.7 Elegant but shzunic from sides 9 - - 54 22 0.8 Elegant - - 63 18 - Elegant 11 - - 66 11 0.4 Elegant (layer on bottom) 12 - - - 57 0.5 Elogant Sorbitol and Glycerol have glass transitions at < 10 C. The DSC scan range did not include temperatures in this range.
n/c = not clear 5 Tv. = Temperature at which partial collapse occurs in tlie free.ae_dry microscope T = Temperature at which total collapse oaazrs in the freeae-dry microscope Tt = Glass transition temperature 10 With the exception of mannitol:lysine, all of the formulations appeared to have adequate physical appearance. Lysine interfered with the crystallization of both WO 00/48635 1'CTMS00/40068 mannitol and glycine, which caused a depression in the glass transition temperature and a collapse of t he lyophilized cake.
Example 6 The Factor VIIi compositions descnbed in Table 8 above were placed in storage at -70 C, 25 C, 40 C, and 50 C for varying lengths of time in order to evaluate their stability. Factor VIII activity levels werc evaluated after 2 weeks, I
month, 2 months, and 3 months, and the results are summarized in Table 10 below. Two of the samples, one employing mannitol as the bulking agent and sorbitol as the stabilizer, and the other employing mannitol as the bulldng agent t 0 and glycerol as the stabilizer, exhibited poor stability. The remaining formulations all exlnbited the ability to stabilize Factor VAI. }
Table 10 Formulation Temperahme % of initial at month Description ( C) 0 0.5 1 2 3 Glycine:Sucrose -70 100.00 97.43 101.71 99.89 97.97 25 100.00 85.44 40 100.00 79.87 71.52 63.06 50 100.00 76.34 67.99 52.14 47.64 Glycine:Trehalose -70 100.00 89.22 96.00 95.90 94.64 25 100.00 83.17 40 100.00 - 79.93 72.42 68.03 50 100.00 80.97 64.28 57:60 50.92 Mannitol:Trehalose -70 100.00 91.32 97.72 96.10 98.26 25 100.00 85.79 40 100.00 82.54 70.72 59.44 50 100.00 66.16 65.51 48.81 52.06 Mannitol:Sucrose -70 100.00 100.45 100.56 105.47 99.22 25 100.00 87.04 40 100.00 85.59 80.78 55.42 50 100.00 81.68 75.53 57.88 43.46 WO 00148635 PCTlUS00l40068 Mannitol:Arginine -70 100.00 102.26 105.53 103.72 105.08 25 100.00 95.15 40 100.00 91.53 80.93 69.19 50 100.00 82.28 68.06 56.32 45.94 Mannitol:Raffinose -70 100.00 93.88 98.41 100.68 103.62 25 100.00 83.13 40 100.00 81.09 73.61 67.16 50 100.00 71.69 8.52 54,25 7.11 Mannitol:Glycerol -70 Mannitol:Sorbitol -70 100.00 104.06 25 100.00 40 100.00 50 100:00 32.73 HES:Sucrose -70 100.00 102.74 103.03 100.90 25 100.00 40 100.00 76.89 77.47 50 100.00 71.47 67.40 30.02 NaC1:Sucrose -70 100.00 88.54 88.44 95.58 25 100.00 40 100.00 7.1.56 58.30 50 100.00 52.71 37.90 3034 Alanine:Sucrose -70 100.00 109.78 109.67 108.96 25 100.00 40 100.00 92.99 73.03 50 100.00 83.25 74.91. 57.65 Glycine:Raffinose -70 100.00 11.1.57 114.51 105.25 25 100.00 40 100.00 89.20 82.10 50 100.00 93.21 7222 53.24 Example 7 5 Based on the information developed during the studies described in Fxamples and 6, it was decided that candidate formulations having the excipients shown in Table 11 below would be further developed.
WO 00/48635 PC'1YUS00/40068 Table 11 Excipient Concentration mannitol or glycine 6-9'!o arginine or trehalose 1-3%
tween 80 0.005-0.04%
NaCI 200-250 mM
CaC12 .3-5 mM
TRIS 20-30 mM
histidine or HEPF.S 10-50 mM
glutathione 0.15-025 mg/ml Based on these parameters, the following specific formulations were developed:
Table 12 Formulation #1 Formulation #2 Formulation #3 l OmM HEPES 10mM BEPES 10mM IIEPES
20mM Tris 20mM Tris 20mM Tris 225mM NaCI 225mM NaCI 225mM NaC1 0.03% (v/v) Tween-80 0.03% (v/v) Tween-80 0.03% (v/v) Twoen-80 8'/o (wlv) mannitoi 8% (wlv) glycine 8% (w/v) mannitol 2% (w/v) trehalose 2% (w/v) trehalose 2'/o (w/v) arginine 02 mg/ml reduced 03 mg/ml reduced 0.2 mg/ml reduced glutatbione glutathione glutathione 4 mM CaClz- 4 mM CaC12 4 mM CaC12 WO 00/48635 PCTI[1S00/40068 Fotmnlation #4 Formulation #5 25mM histidine 25mM histidine 20mM Tris 20mM Tris 225mM NoO 225mM NaCI
0.03% (v/v) Twoen-80 0.03% (v/v) Tween-80 8% (w/v) msamitol 89/0 (w/v) glycine 2% (w/v) trehaloso 2% (w/v) trehalose 02 mg/nil reduced 0.2 mghnl reduced glutathione glutathione 4 mM CaC12 4 mM CaC12 , = .~ .
~
i . .
molecule.
While the Factor VIII compositions descnbod in this application can be s lyophilized and reconstituted in the indicated concentrations, one of skill in the art wiil undecstand that these preparations can also be reconstituted in more dilute form. FoT example, a praparation according the present invention which is lyopbilized and/or normally reconstituted in 2 ml of solution can also be reconstituted in a larger volume of diluent, such as 5 ml. This is particulariy t o appropriate when the Factor VIII preparation is being injected into a patient immediately, since in this can the Factor VIII is less likely to lose activity, ti which may occur more rapidly in more dilute solutions of Factor VIII.
Formulation and Lyophilization Development is In order to achieve maximal stability, the Factor VIII compositions of the present invention are preferably Iyophiliaed. During lyophiization, Factor VIII
A =
= . ~ . ~ is converted from being in an aqueous phase to being in an amorphous solid phase, which is thought to protect the protein from chemical and/or conformational instability. The lyophilized preparation not only contains an 26 amorphous phase, but also includes a component which crystallizes during lyophilization. This is thought to allow the rapid lyophilization of the Factor ) VIII composition and the formation.of a mqre elegant cake (that is, a cake with minimal shrinkage from the sides of the container in which it was lyophiiized).
In the formulations of the present invention, the stabilizing agents have been 25 selected to exist primarily in an amorphous phase of the lyophilizel product, while the bulking agents (except HES) have been selected to crystallize during freezing.
WO 00148635 pCT/t1S00/40068 Both the Factor VIiI and the stabilizer are preferably dispersed in the amorphous phase of the lyophiliwd cake. The mass of the stabilizer is also preferably large compared to the o8ier excipients in the amorphous form. In addition, the apparent glass transition temperature (T,,') of the amorphous phase 5 is preferably relatively high during freeze-drying, and the glass transition temperature (Tg) of the solid is likewise preferably high during storage.
Crystallization of sodium chloride in the product was found to be desirable, since amorphous sodium chloride will depress the T.' of the amorphous phase.
10 In order to avoid the collapse of the cake of a particular composition, primary drying is preferably carried out at a product temperature bedow. the apparent glass transition temperature of the fceeze concentrate. An increase in drying time may also be required to offset a decrease in Ts . Further information on lyophilization may be found in Carpenter, J.F. and Chang, B.S., Lyophilization is ofProtein Pharmaceuticals, Biotechnology and Biophannaceutical Manufacturin8, Processing and Preservation, K.E. Avis and V.L. Wu, eds.
~ . =
(Buffalo Grove, IL: Interpharm Press, Inc.), pp. 199-264 (1996).
Example 1 2o The effects of the concentration of Factor VIII and of the addition of a stabilim on the recovery of Factor VIII were investigated in several studies. These studies were performed using mannitol as a model bulking agent and sucrose as a model stabilizer. The three sample formulations descn'bed in Table 3 below were used in these studies. AU formulations used in these studies included 10 - mM Tris, 200 mM NaC1, 8% mannitol, 4 mM CaC12; and 0.02% Tween-80 and were conducted at pH 7Ø
WO 00148635 PC7'/USOO/40068 IG
Table 3 Sample Initial Factor VIII Sucrose %
I.D. (IU/ml) These samples were lyophilized using the fieer.e-drying cycle shown in Table 4 below in order to maintain a product temperature below the apparent glass transition temperature (T..'). Differential scanning calorimetric (DSC) studies indicated the presence of a trnnsition at approximately -40 C in the mannitol formulations. In order to maintain a product temperature below this value, the shelf temperature was set to -32 C during primary drying. Primary drying under these conditions was perfonned for about 55 hours, with a total cycle time of about 80 hours.
WO 00/48635 PCT/i)S00/40068 Table 4 Freezing/Processing Description Method I Cool to +5 C;
(Freezing) Cool to -5 C at 1 C/minute, hold for 20 minutes;
Cool to 20 + 5 C at I C/niinute; hold for 1 hour (up to 3 hours);
Cool to -45 C at 0.5 C/minute, hold for 1 hour.
II Freeze per method I
Hold at 35 C for 48 hours.
~ Freeze per method I
Hold at -35 C for 48 hours;
Hold at 20 C for 48 hours.
IV Shelf -32 C during primaiy drying for (Freeze-drying) about 55 hours (up to 100 hours);
Product < -40 C durin8 pnnar'y drying:
Ramp fratn -32 C to +40 C at 0.2 Gminute;
Shelf +40 C during secondary drying for 3 hours.
The Factor VIII activity of these samples, as determined by the one-stage clotting assay, was compared against a control held at -45 C. The assay results are shown in Table 5 below.
Table 5 Processing % Loss in Factor. VIII Activity During Each Step Method Formulation IA Formulation IB Formulation IC
(600 IUhn1) (60 IIJ/ml) (60 IU/ml, 2%
Sucrose) I 6.7 37.5 41.7 II 2.0 9.3 3.9 III 7.3 11.6 5.0 IV 20.0 24.2 18.3 (Lyophilization) These results indicate that protein concentration has an effect on the recovery of .
Factor VIII during freezing. Formulations containing 60 IU/mi lost approximately 37 /.-42% of the initial Factor VIII activity duriag the frcezing step, while 6.7% of Factor VIII activity was lost for the formulation containiag 600 IU/ml. These results indicate that a higher protein concentration has a protective effect during freezing. Although sucrose provided some protection to the Factor VIII duzing tho intermediate tempera'ture holds as well as during freeze-drying, it failed to protect the protein during the initial freezing step.
Ezamaie 2 Following the development of the lyophilization process outlined in Example 1, fiuther optimization of this process was undertalcen. It has been found that a lyophilized composition having a higher giass transition teanperature, (and, theoretically, better Factor VIII stability) can be produced by: (1) lowering the freezing temperature initially to -45 C or lower (such as down to about -50 C
or -55 C); (2) raising the temperature to -20 C or -22 C (+5 C); and then (3) lowering the temperature again to 45 C or lower. The temperature is lowered or raised, as the case may be, at a rate of between about 0.5 C and about 1.0 C
per minute. Once the desired temperature is reached, the composition is held at that temperature for betweea I and 3 hours. This improved freezing cycle is shown in Table 6 below.
Table 6 Freezing Method Description I Cool to +5 C;
Cool to -5 C at 0.5-1 C/minute, hold for 20 n2inntes;
Cool to between-55 C and 45 C at 0.5-1 C/minute, hold for about 1 hour, Warm to 22 C ( 5 C) at 0.5-1 Cfminute, hold for I to 3 hours;
Cool to -45 C at 0.5-1 Clminute, hold for about 1 hour.
=, .
' 10 Unless otherwise indicated, the temperatures referred to in this example and in other examples refer to the shelf tcmpGrature of the lyophilizer and not to the temperature of the product per se. Following the improved fiwzing cycle, the remainder of the lyophilization process can be conducted as outlined in Example I above, or otherwise as descn'bed fnrther herein or as determined by one of sidll in the art.
This improved lyophilization procxss was found to be useful for formulations which include glycine as the bulking agent as we11 as those which use mannitol.
It is fn:ther beiieved to have applicability to formulations which make use of the other bulkiing agents of the present invention as well.
Example 3 It is believed that in order to produce a freem-dried product with acceptable cake appearance and glass transition temperature, the bulking agent of lyophilized pharmaceutical preparations which contain sodium chloride, such as 5 glycine or mannitol, may need to be crystallized. The following improved lyophilization process for crystallizable bulldn.g agents was therefore developed Table 7a - Freezing Steps Process Step Temperature Duration of Step Initial fireezing -40 C or less 1 hour First annealing between 23 C and 27 C 3 hours Second freezing -55 C 1 hour Second annealing -36 C 4 hours Third fieezing -50 C 1 hour Table 7b - Freeze-Drying Steps Process Step Temperature Duration of Step Primary Drying -35 C up to 100 hours Secondary Drying: First step 40 C 3 hours Secondary Drying: Second step 45 C 3 hours Secondary Drying: Tbird step 50 C 3 hours In the freezing steps, changes in the temperatures occurred at a rate of between about 0.5 C/minute and 1 C/minute. It is believed that steps of longer duration would also be effective.
Prior to the first freezing step, the temperature is brought to between about and 8 C for about one hour for the purpose of bringing all the vials to approximately the same temperature. After this the lyophilizer is cooled to -C. The first free2ing step should be performed at a temperature less than -s 30 C, preferably below 35 C, and more preferably at about -40 C: Following this, the first annealing step should occur at a temperature of between -30 C
and -19 C, more preferably either between about 25 C and -28 C (if glycine is the bulking agent) or between 21 C and 24 C (if numnitol is the bulking agent), with the temperatures of 23 C and 26 C being most preferred, at which 1 o temperatures it is believed that the ciystallizable bullcing agents crystallize, at least in part. However, the lower range around 27 C is not recommended for formulations containing mannitol and arginine. This step is preferably carried out for about 3 hours.
13 Following the first annealing step, the temperature is lowered, preferably to kss than about 50 C and more preferably to less than 55 C, for about 1 hour. It is ~.. -. believed that the sodium chloride in the preparation nucleates at this time.
During the second annealing step, the temperature of the pharmaceutical 2o preparation is raised to between about 30 C and ,39 C, and preferably to about -33 C for mannitol-containing compositions and -36 C for glycine-containing compositions. It is believed that AlaCl crystal growth occurs at this time, at least in part. This step is preferably conducted for about 4 hours. Following this, the temperature of the lyophilizer is reduced to about -SO C, preferably for about 25 hour in order to reduoe the temperature of the preparation.
In the freeze-drying steps which follow, changes in temperature occurred at a rate of between about 0.1 C/minute and o.S C/minute. After reducing the pressure in the lyophilizer to about 65 mTorr, the temperature is raised to between about -32 C and -35 C for primary drying. Ice crystals in the preparation will sublimate at this temperature. This step is performed for up to about 100 hours, or until most of the ice has been sublimated fiom the preparation. The point at which most of the ice has sublimated can be detecmined, for example, using a dewpoint sensor, which indicates the end of the sublimation of ice when the readings decrease (the point of inflection).
Following primary drying, the temperature is raised to +40 C, preferably at a rate of 0.2 C/minute, to initiate secondary drying to remove further water from the preparation. This temperature is preferably maintained for about three hours. Second and third secondary dtying steps follow this first step, where the temperature is raised to about +45 C for about three hours and then to about +50 C for three more hours in order to reduce the moisture in the lyophilized cake to less than 2% (w/w).
Example 4 ~:::= Further studies were performed to examine specifically the effect of histidine on lyophilized Factor VIII compositions containing glycine or snannitol as bullcing agents. Non-reversing heat flow (Modulated DSC, mDSC) was used to detect the crystallization of these bulldng agents during cooling. Both the temperature of crystallization and the total heat of crystallization were determined from the crystallization exotherm. The appearance of the NaCI eutectic melt endotherm during warming was used to detect NaCI 'crystall.ization. In mDSC, the extent of crystallization was detennined as the ratio of the enthalpy of melting of the formulation to the enthalpy of inelting of pure NaCI solution by using the total heat flow signal. In addition, X-ray diirraction analyses were performed in order to determine the extent of crystallization in the lyophilized formulations.
While histidine concentrations less than 20 mM did not significantly impaet the crystallization of glycine, 50 mM histidine reduced the extent of glycine crystallization. Well-defined NaCI crystallization exotherms were not observed during cooling of fonnulations containing glycine. However, cutectic melting endotherms during heating indicated that NaCI was crystallized (> 50%) after cooling lower than -50 C and annealing at _ 30 C, -35 C and -40 C. The inclusion of 50 mM histidine in the glycine-oontaining formulation retarded NaCI crystallization. Consequently, the annealing time was increased 3-fold for such fonnulations in order to achieve an equivalent crystallinity.
However, the effect of 20 mM histidine on the crystallization of NaCI in the glycine-containing fomnulations was minimal. In fiuze-drying studies, collapse of the lyophilized cake was observed visually in glycine-containing formulations containing 50 mM histidine. X-ray powder diflicaction data indicated a decrease in the crystallinity of NaCI in samples containing histidine.
In mannitnl-containing formulations, typically 83% - 90% of the sodium chloride crystallized during cooling betweea -40 C and 50 C without the need for annealing. While inclusion of 20 mM histidine to the formulation suppressed NaC1 crystallization during cooling, annealing resulted in approximately 40% crystallization of the NaCI.
Tberefore, in formulations containing a crystallizable bulking agent, such as glycine or mannitol, and NaCI, the inclusion of histidine may decrease the extent of crystalliution of NaCl. tllthough this could in some cases lead to the - collapse of the cake which is formed during lyophdization, the use of relatively lower concentrations of histidine in such fomaulations.can mitigate this effect.
Nonetheless, acceptable cakes have been fonned with concentrations of histidine of 35 mM and 50 mM. Histidine may also be preferable to FI;EPHS as a buffer in mannitol- and glycine-based formulations, as the use of HERIrS.
has been observed to lower the Tg' to a greater extent than a similar amount of histidine.
Example 5 The physical characteristics of a number of potential Factor VIII
formulafions, including seven candidate stabilizers and five bulking agents, were evaluated in another stndy. In addition to a bulking agent and stabilizer, all formulations listed in Table 8 below (except for formulation 11) contained 10 mM Tris=HC1, 200 mM NaC1, 0.02'/o Tween-80, 4 mM CaC12 and were at pH 7Ø Formulation 11 contained 10 mM Tris*HCl, 0.02% Tween-80, and 4 mM CaCl2, also at pH
7Ø All pH measurements were performed at ambient temperature.
Table 8 Sample Buiking Agent Protein I D. Stabilizer 1 80/0 Mannito] 2% Sucrose 2 8% Mannitol 2% TreWose 3 8% Mannitol 2% Raffinose 4 8'/o Mannitol 2% Arginine 5 8% Mannitol 2% Lysine 6 8% Mantritol 2% Sorbitol 7 8% Mamutol r/o Glycxrol 8 4% Hydroxyethyl 2% Sumse Starch 9 8% Glycine 2% Sucrose .~ , ~ ' .'. == = ' 10 8% Glycine . 2% Trehalose , 11 400 mM NaCI 20/o Sucrose 12 8% Alanine 2% Sucwse Collapse temperature mcasuremeats by freeze-dry microscopy and thermal S transition measurements by DSC were used to predict fleme-drying behavior.
DSC, X-ray powder diffiaction and polarized light microseopy were also used to determine the crystallinity of the lyophilized sampks. The reconstitution time and the appearance of the samples were aLso evaluated. The results of all of these measuretnents are summarized in Table 9 below.
Table 9 Sample TV. T, Ts Reconstitution Water LD. ( C) ( C) ( C) (seconds) Conteat APpearance 1 -14 -10 54 64 n/c Elegant 2 -20 -15 53 62 1.4 Top partially collapsed 3 -15 -10 54 77 1.7 Elegant 4 - - - - - Partial collapse - - - - Collapsed 6 n/c n/c < 10 C' 63 0.6 Elegant 7 < 10 C' - - Elegant 8 - - 86 49 0.7 Elegant but shzunic from sides 9 - - 54 22 0.8 Elegant - - 63 18 - Elegant 11 - - 66 11 0.4 Elegant (layer on bottom) 12 - - - 57 0.5 Elogant Sorbitol and Glycerol have glass transitions at < 10 C. The DSC scan range did not include temperatures in this range.
n/c = not clear 5 Tv. = Temperature at which partial collapse occurs in tlie free.ae_dry microscope T = Temperature at which total collapse oaazrs in the freeae-dry microscope Tt = Glass transition temperature 10 With the exception of mannitol:lysine, all of the formulations appeared to have adequate physical appearance. Lysine interfered with the crystallization of both WO 00/48635 1'CTMS00/40068 mannitol and glycine, which caused a depression in the glass transition temperature and a collapse of t he lyophilized cake.
Example 6 The Factor VIIi compositions descnbed in Table 8 above were placed in storage at -70 C, 25 C, 40 C, and 50 C for varying lengths of time in order to evaluate their stability. Factor VIII activity levels werc evaluated after 2 weeks, I
month, 2 months, and 3 months, and the results are summarized in Table 10 below. Two of the samples, one employing mannitol as the bulking agent and sorbitol as the stabilizer, and the other employing mannitol as the bulldng agent t 0 and glycerol as the stabilizer, exhibited poor stability. The remaining formulations all exlnbited the ability to stabilize Factor VAI. }
Table 10 Formulation Temperahme % of initial at month Description ( C) 0 0.5 1 2 3 Glycine:Sucrose -70 100.00 97.43 101.71 99.89 97.97 25 100.00 85.44 40 100.00 79.87 71.52 63.06 50 100.00 76.34 67.99 52.14 47.64 Glycine:Trehalose -70 100.00 89.22 96.00 95.90 94.64 25 100.00 83.17 40 100.00 - 79.93 72.42 68.03 50 100.00 80.97 64.28 57:60 50.92 Mannitol:Trehalose -70 100.00 91.32 97.72 96.10 98.26 25 100.00 85.79 40 100.00 82.54 70.72 59.44 50 100.00 66.16 65.51 48.81 52.06 Mannitol:Sucrose -70 100.00 100.45 100.56 105.47 99.22 25 100.00 87.04 40 100.00 85.59 80.78 55.42 50 100.00 81.68 75.53 57.88 43.46 WO 00148635 PCTlUS00l40068 Mannitol:Arginine -70 100.00 102.26 105.53 103.72 105.08 25 100.00 95.15 40 100.00 91.53 80.93 69.19 50 100.00 82.28 68.06 56.32 45.94 Mannitol:Raffinose -70 100.00 93.88 98.41 100.68 103.62 25 100.00 83.13 40 100.00 81.09 73.61 67.16 50 100.00 71.69 8.52 54,25 7.11 Mannitol:Glycerol -70 Mannitol:Sorbitol -70 100.00 104.06 25 100.00 40 100.00 50 100:00 32.73 HES:Sucrose -70 100.00 102.74 103.03 100.90 25 100.00 40 100.00 76.89 77.47 50 100.00 71.47 67.40 30.02 NaC1:Sucrose -70 100.00 88.54 88.44 95.58 25 100.00 40 100.00 7.1.56 58.30 50 100.00 52.71 37.90 3034 Alanine:Sucrose -70 100.00 109.78 109.67 108.96 25 100.00 40 100.00 92.99 73.03 50 100.00 83.25 74.91. 57.65 Glycine:Raffinose -70 100.00 11.1.57 114.51 105.25 25 100.00 40 100.00 89.20 82.10 50 100.00 93.21 7222 53.24 Example 7 5 Based on the information developed during the studies described in Fxamples and 6, it was decided that candidate formulations having the excipients shown in Table 11 below would be further developed.
WO 00/48635 PC'1YUS00/40068 Table 11 Excipient Concentration mannitol or glycine 6-9'!o arginine or trehalose 1-3%
tween 80 0.005-0.04%
NaCI 200-250 mM
CaC12 .3-5 mM
TRIS 20-30 mM
histidine or HEPF.S 10-50 mM
glutathione 0.15-025 mg/ml Based on these parameters, the following specific formulations were developed:
Table 12 Formulation #1 Formulation #2 Formulation #3 l OmM HEPES 10mM BEPES 10mM IIEPES
20mM Tris 20mM Tris 20mM Tris 225mM NaCI 225mM NaCI 225mM NaC1 0.03% (v/v) Tween-80 0.03% (v/v) Tween-80 0.03% (v/v) Twoen-80 8'/o (wlv) mannitoi 8% (wlv) glycine 8% (w/v) mannitol 2% (w/v) trehalose 2% (w/v) trehalose 2'/o (w/v) arginine 02 mg/ml reduced 03 mg/ml reduced 0.2 mg/ml reduced glutatbione glutathione glutathione 4 mM CaClz- 4 mM CaC12 4 mM CaC12 WO 00/48635 PCTI[1S00/40068 Fotmnlation #4 Formulation #5 25mM histidine 25mM histidine 20mM Tris 20mM Tris 225mM NoO 225mM NaCI
0.03% (v/v) Twoen-80 0.03% (v/v) Tween-80 8% (w/v) msamitol 89/0 (w/v) glycine 2% (w/v) trehaloso 2% (w/v) trehalose 02 mg/nil reduced 0.2 mghnl reduced glutathione glutathione 4 mM CaC12 4 mM CaC12 , = .~ .
~
i . .
Claims (3)
1. A Factor VIII composition formulated without adding albumin to said composition, comprising the following formulation excipients in addition to Factor VIII:
300 mM to 500 mM NaCl;
1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine;
1 mM to 5 mM calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and 8.
300 mM to 500 mM NaCl;
1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine;
1 mM to 5 mM calcium salt; and a buffering agent for maintaining a pH of approximately between 6 and 8.
2. The composition of claim 1, wherein the NaCl is present in an amount of about 400 mM.
3. Use of a Factor VIII composition according to any one of claims 1 to 2 for the preparation of a medicament for the treatment of hemophilia.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25527999A | 1999-02-22 | 1999-02-22 | |
| US09/255,279 | 1999-02-22 | ||
| US45275299A | 1999-12-01 | 1999-12-01 | |
| US09/452,752 | 1999-12-01 | ||
| CA2362927A CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2362927A Division CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2634674A1 true CA2634674A1 (en) | 2000-08-24 |
Family
ID=26944588
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2362927A Expired - Lifetime CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
| CA002634674A Abandoned CA2634674A1 (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
| CA2634664A Expired - Lifetime CA2634664C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
| CA002634663A Expired - Lifetime CA2634663C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2362927A Expired - Lifetime CA2362927C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2634664A Expired - Lifetime CA2634664C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
| CA002634663A Expired - Lifetime CA2634663C (en) | 1999-02-22 | 2000-02-22 | Novel albumin-free factor viii formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US6586573B1 (en) |
| EP (5) | EP1154796B1 (en) |
| JP (9) | JP5149470B2 (en) |
| CN (3) | CN101683522B (en) |
| AT (1) | ATE365052T1 (en) |
| AU (1) | AU777972B2 (en) |
| BR (1) | BR0008405B1 (en) |
| CA (4) | CA2362927C (en) |
| CY (2) | CY1108030T1 (en) |
| CZ (3) | CZ300547B6 (en) |
| DE (1) | DE60035260T2 (en) |
| DK (4) | DK2130554T3 (en) |
| ES (4) | ES2435141T3 (en) |
| HK (4) | HK1139862A1 (en) |
| MX (1) | MXPA01008515A (en) |
| PL (4) | PL203177B1 (en) |
| PT (4) | PT1820516E (en) |
| RU (1) | RU2244556C2 (en) |
| WO (1) | WO2000048635A1 (en) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
| US6586573B1 (en) * | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| US6830917B2 (en) * | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
| EP1458408B1 (en) | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
| KR20040065278A (en) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | Liquid composition of modified factor vii polypeptides |
| US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
| US6982080B2 (en) * | 2002-03-15 | 2006-01-03 | Wyeth | Hydroxyethyl starch—containing polypeptide compositions |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| CN1671410B (en) * | 2002-06-21 | 2010-05-12 | 诺和诺德医疗保健公司 | Stabilised solid compositions of factor VII polypeptides |
| GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
| JP2006524195A (en) * | 2003-03-18 | 2006-10-26 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Liquid aqueous pharmaceutical composition of factor VII polypeptide |
| US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| KR20060015574A (en) * | 2003-05-23 | 2006-02-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Protein stabilization in solution |
| JP4658041B2 (en) | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Liquid composition of factor VII polypeptide |
| WO2005002615A1 (en) * | 2003-07-01 | 2005-01-13 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| DE10333317A1 (en) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulation for protein medicines without the addition of human serum albumin (HSA) |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| KR100560697B1 (en) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | Formulation of albumin-free erythropoietin |
| AU2004264282B2 (en) * | 2003-08-14 | 2010-10-14 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of Factor VII polypeptides |
| EP1670507A4 (en) * | 2003-09-12 | 2007-10-17 | Antigenics Inc | Vaccine for treatment and prevention of herpes simplex virus infection |
| MXPA06006886A (en) * | 2003-12-19 | 2006-09-04 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor vii polypeptides. |
| GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| CA2554018A1 (en) * | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
| CA2557061C (en) * | 2004-03-19 | 2013-08-20 | Baxter International Inc. | Factor ixa for the treatment of bleeding disorders |
| US7319032B2 (en) * | 2004-04-22 | 2008-01-15 | Medtox | Non-sugar sweeteners for use in test devices |
| KR100624013B1 (en) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | Pharmaceutical preparation of recombinant factor ? lyophilized without albumin as a stabilizer |
| CN101163506B (en) | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | Polymer-von willebrand factor-conjugates |
| FR2881139A1 (en) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Liquid for lyophilization of proteins, useful for stabilizing pharmaceuticals or analytical proteins, comprises a filler, stabilizer, buffer and optionally nonionic surfactant |
| WO2007014073A2 (en) * | 2005-07-22 | 2007-02-01 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| CA2626531C (en) | 2005-11-01 | 2011-11-29 | Wyeth | Sodium chloride solution for drug reconstitution or dilution |
| EP2233137B1 (en) * | 2005-11-09 | 2014-04-30 | Ajinomoto Co., Inc. | Calcium receptor activator |
| US8420144B2 (en) * | 2005-11-09 | 2013-04-16 | Ajinomoto Co., Inc. | Kokumi-imparting agent, method of using, and compositions containing same |
| EP2327986B1 (en) * | 2005-11-09 | 2013-05-29 | Ajinomoto Co., Inc. | Kokumi-imparting agent |
| BRPI0618893A2 (en) * | 2005-11-22 | 2011-09-13 | Wyeth Corp | immunoglobulin fusion protein formulations |
| PT1969004E (en) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| AU2007245190B2 (en) | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| PL2029740T3 (en) * | 2006-05-31 | 2012-11-30 | Genzyme Corp | Use of polysaccharides for promotion of enzymatic activity |
| EP2077718B2 (en) | 2006-10-27 | 2022-03-09 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
| CN101808657A (en) * | 2006-11-07 | 2010-08-18 | 赛诺菲巴斯德生物制剂公司 | Stabilization of vaccines by lyophilization |
| CN101557830B (en) | 2006-12-15 | 2016-06-08 | 巴克斯特国际公司 | There is the factor VIIa-Polysialic acid conjugate of the Half-life in vivo of prolongation |
| FR2913020B1 (en) | 2007-02-23 | 2012-11-23 | Biomethodes | NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS |
| EA019345B1 (en) * | 2007-03-05 | 2014-03-31 | Кадила Хелзкэр Лимитед | Compositions comprising peg-interferon alpha conjugates and raffinose as cryoprotectant |
| AU2013204652B2 (en) * | 2007-04-26 | 2015-06-18 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
| EP2150264A4 (en) * | 2007-04-26 | 2014-09-24 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
| AU2008249287C1 (en) * | 2007-05-08 | 2015-06-04 | Ajinomoto Co., Inc. | Low-fat food |
| US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
| US9034818B2 (en) * | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
| CN101376022B (en) * | 2007-08-31 | 2011-11-30 | 上海医药工业研究院 | Medicament composition containing defibrase modified by PEG |
| US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
| US20100316625A1 (en) * | 2007-12-21 | 2010-12-16 | Inspiration Biopharmaceuticals, Inc. | Stabilized factor ix formulations containing trehalose |
| SG10201503304RA (en) | 2007-12-27 | 2015-06-29 | Baxter Int | Cell culture processes |
| EP2113564A1 (en) * | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
| WO2010017296A1 (en) * | 2008-08-05 | 2010-02-11 | Wyeth | Lyophilization above collapse |
| CA2732423A1 (en) | 2008-08-21 | 2010-02-25 | Octapharma Ag | Recombinantly produced human factor viii and ix |
| MX2011002159A (en) * | 2008-08-27 | 2011-03-29 | Schering Corp | Lyophilized formulatons of engineered anti-il-23p19 antibodies. |
| PL2337580T3 (en) * | 2008-09-03 | 2012-08-31 | Octapharma Ag | Stabilized compositions for recombinantly produced factor viii |
| MX2011002372A (en) * | 2008-09-10 | 2011-04-04 | Genentech Inc | Compositions and methods for the prevention of oxidative degradation of proteins. |
| CN102202683A (en) * | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| ES2706296T3 (en) * | 2008-11-07 | 2019-03-28 | Univ Connecticut | Formulations of Factor VIII |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2533619C2 (en) | 2009-07-27 | 2014-11-20 | Лайпоксен Текнолоджиз Лимитед | Glycopolysialylation of proteins, which are not blood clotting proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| KR101832937B1 (en) | 2009-07-27 | 2018-02-28 | 박스알타 인코퍼레이티드 | Blood coagulation protein conjugates |
| GB0915480D0 (en) | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| AU2010295299B2 (en) | 2009-09-21 | 2015-12-24 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized ADAMTS13 formulations |
| US20130131192A1 (en) | 2009-11-03 | 2013-05-23 | Grifols Therapeutics Inc. | Composition, method, and kit for alpha-1 proteinase inhibitor |
| WO2011066291A2 (en) * | 2009-11-24 | 2011-06-03 | Talecris Biotherapeutics, Inc. | Lyophilization methods, compositions, and kits |
| RU2682720C2 (en) * | 2010-01-19 | 2019-03-21 | Ханми Сайенс Ко., Лтд. | Liquid formulations for long-acting erythropoietin conjugate |
| CN102811681B (en) | 2010-03-23 | 2016-10-12 | 爱德华兹生命科学公司 | The method of regulation lamellar bioprosthetic tissue |
| US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
| DK2616090T3 (en) * | 2010-09-17 | 2023-09-18 | Takeda Pharmaceuticals Co | STABILIZATION OF IMMUNOGLOBULINS BY AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACID TO NEUTRAL PH |
| CA2814054A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| DK2632478T3 (en) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS |
| JP5922141B2 (en) | 2010-11-05 | 2016-05-24 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | Novel variant of antihemophilic factor VIII with increased specific activity |
| US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
| EP2651433A1 (en) * | 2010-12-16 | 2013-10-23 | Novo Nordisk A/S | Aqueous factor viii solution |
| HUE049352T2 (en) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| BRPI1105317A2 (en) | 2011-01-24 | 2013-04-30 | Fundacco Hemoct De Ribeirco Preto | stable and large-scale production of human fviii in human cell line sk-hep-1 |
| LT2691112T (en) | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| CN103703141B (en) | 2011-04-08 | 2016-08-17 | 伯乐实验室公司 | There is the PCR reactant mixture of the nonspecific activity of reduction |
| SG194032A1 (en) | 2011-04-08 | 2013-11-29 | Bio Rad Laboratories | Sso7-polymerase conjugates with decreased non-specific activity |
| US20140227250A1 (en) | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
| CA2905739A1 (en) * | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Recombinant factor viii formulations |
| US9623088B2 (en) * | 2013-03-15 | 2017-04-18 | Bioverativ Therapeutics Inc. | Factor VIII polypeptide formulations |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| KR102058864B1 (en) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | Pharmaceutical composition having improved stability comprising a fusion protein of factor vii |
| KR20160146762A (en) * | 2014-04-01 | 2016-12-21 | 어드밴텍 바이오사이언스 파마큐티카 엘티디에이 | Stable factor viii formulations with low sugar-glycine |
| AU2015240354A1 (en) * | 2014-04-01 | 2016-11-17 | Advantech Bioscience Farmaceutica Ltda. | Stabilization of Factor VIII without calcium as an excipient |
| EP3177317B1 (en) * | 2014-08-04 | 2020-03-18 | CSL Limited | Factor viii formulation |
| SG11201701247RA (en) * | 2014-08-20 | 2017-03-30 | Portola Pharm Inc | Lyophilized formulations for factor xa antidote |
| JP6949711B2 (en) * | 2014-10-23 | 2021-10-20 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Pharmaceutical composition containing peptide variant and method of use thereof |
| CN107660149B (en) | 2015-04-21 | 2021-04-27 | 舒泰神（北京）生物制药股份有限公司 | Nerve growth factor composition and injection powder |
| EP3287139B1 (en) | 2015-04-21 | 2021-08-11 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Nerve growth factor composition and injection powder |
| WO2017007837A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilizaton of proteins |
| WO2017007835A1 (en) | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for nanoemulsion vaccine formulations |
| US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
| EP3167877A1 (en) * | 2015-11-12 | 2017-05-17 | Bayer Pharma Aktiengesellschaft | Method for the production of freeze-dried pellets comprising factor viii |
| WO2017147522A1 (en) * | 2016-02-24 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
| JP7109427B2 (en) * | 2016-06-01 | 2022-07-29 | セルヴィエ アイピー ユーケー リミテッド | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| JP6854351B2 (en) * | 2016-12-21 | 2021-04-07 | スン・チュン・チンＣｈｕｎｇ Ｃｈｉｎ ＳＵＮ | A novel method for preserving plasma protein activity |
| EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| JP6630315B2 (en) | 2017-06-27 | 2020-01-15 | 矢崎総業株式会社 | Noise reduction unit |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR20210113271A (en) * | 2019-01-06 | 2021-09-15 | 엔도 글로벌 에스테틱스 리미티드 | Collagenase formulation and method for preparing same |
| CN114072420A (en) | 2019-07-04 | 2022-02-18 | 康诺贝林伦瑙有限公司 | Truncated Von Willebrand Factor (VWF) for increasing the in vitro stability of factor VIII |
| CN110772487B (en) * | 2019-12-09 | 2021-09-21 | 湖南科伦制药有限公司 | Freeze-drying method of ethylenediamine diaceturate |
| CN112121009B (en) * | 2020-09-24 | 2022-12-02 | 科兴生物制药股份有限公司 | New preparation of polyethylene glycol modified recombinant human granulocyte stimulating factor |
| BR112023005377A2 (en) | 2020-09-24 | 2023-04-25 | Merck Sharp & Dohme Llc | STABLE FORMULATIONS OF PROGRAMMED DEATH 1 (PD-1) RECEPTOR ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF, AND METHODS OF USE THEREOF |
| US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
| WO2022217041A1 (en) * | 2021-04-09 | 2022-10-13 | Hyalo Technologies, LLC | Method of sterilization of biologics |
| WO2023017020A1 (en) * | 2021-08-11 | 2023-02-16 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
| CN114015758B (en) * | 2021-10-15 | 2022-06-24 | 无锡百泰克生物技术有限公司 | Freeze-drying protective agent, fluorescent PCR detection kit and freeze-drying process |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB941019A (en) | 1961-04-27 | 1963-11-06 | Crookes Lab Ltd | Improvements in and relating to the stability of anti-haemophilic globulin (factor viii) |
| US3389314A (en) | 1962-05-07 | 1968-06-18 | Penn Controls | Proportional silicon controlled rectifier driven system for a heat motor |
| US3681126A (en) | 1969-11-25 | 1972-08-01 | Monsanto Co | Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride |
| US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
| US3770631A (en) | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
| US4073886A (en) | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
| US3980432A (en) | 1973-04-02 | 1976-09-14 | Behringwerke Aktiengesellschaft | Partial thromboplastin, its use as diagnostic agent and process for preparing it |
| US3893990A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
| US3893991A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
| US4105650A (en) | 1975-04-11 | 1978-08-08 | Edward Shanbrom, Inc. | Method of preserving blood plasma i |
| US4189425A (en) | 1975-04-11 | 1980-02-19 | Edward Shanbrom, Inc. | Method of preserving blood plasma I |
| US4069216A (en) | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
| US4089944A (en) | 1975-12-22 | 1978-05-16 | Baxter Travenol Laboratories, Inc. | Rapidly solubilized AHF composition and process for preparing same |
| US4027013A (en) | 1976-01-22 | 1977-05-31 | William L. Wilson | Clottable fibrinogen free factor VIII and albumin product and process |
| SU663404A1 (en) | 1976-12-30 | 1979-05-25 | Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова | Method of obtaining fibrin monomer |
| US4137223A (en) | 1977-05-16 | 1979-01-30 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
| SE443293B (en) | 1978-01-25 | 1986-02-24 | Blombaeck E G B | Blood fraction FRONT TELL NING |
| DE2916711A1 (en) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blood coagulation factors and process for their manufacture |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| FR2460305A2 (en) | 1979-06-29 | 1981-01-23 | Merieux Inst | PROCESS FOR PREPARING A FACTOR VIII CONCENTRATE |
| US4386068A (en) | 1980-02-26 | 1983-05-31 | Cutter Laboratories, Inc. | Antihemophilic factor concentrate and method for preparation |
| EP0035204B2 (en) | 1980-03-05 | 1991-05-22 | Miles Inc. | Pasteurized therapeutically active protein compositions |
| US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
| US4440679A (en) | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| US4623717A (en) | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| JPS56127308A (en) | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
| JPS56135418A (en) | 1980-03-27 | 1981-10-22 | Green Cross Corp:The | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human |
| AT369263B (en) | 1980-08-27 | 1982-12-27 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) HIGH CONCENTRATE |
| DE3033932C2 (en) | 1980-09-10 | 1984-05-24 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Process for the cold sterilization of preparations containing blood coagulation factor VIII |
| JPS5770814A (en) | 1980-10-17 | 1982-05-01 | Isamu Horikoshi | Oral preparation of blood clotting eighth factor |
| US4495278A (en) | 1981-04-27 | 1985-01-22 | Baxter Travenol Laboratories, Inc. | Process for making novel blood clotting enzyme compositions |
| US4382083A (en) | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
| US4479938A (en) | 1981-06-25 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Therapeutic composition containing factor VIIa |
| JPS5874617A (en) | 1981-10-28 | 1983-05-06 | Green Cross Corp:The | Heat-treating method of aqueous solution containing blood coagulation factor 8 derived from human |
| US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
| US4591505A (en) | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
| US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
| US4495175A (en) | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
| DE3230849A1 (en) | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | PASTEURIZED HUMAN FIBRINOGEN (HF) AND METHOD FOR THE PRODUCTION THEREOF |
| DE3237512A1 (en) | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | METHOD FOR PASTEURIZING ANTIHAEMOPHILIC CRYOPRAEZIPITATE (AHK) AND ANTIHAEMOPHILE CRYOPRAECIPITATE PRODUCED THEREOF |
| GB2129685B (en) | 1982-11-11 | 1985-11-13 | Nat Biolog Standards Board | Anti-haemophilic compositions |
| JPS59134730A (en) | 1983-01-20 | 1984-08-02 | Green Cross Corp:The | Heat treatment of viii factor of blood clotting |
| US4650858A (en) | 1983-03-21 | 1987-03-17 | Nordisk Gentofte A/S | Concentrate of the antihemophilic factor VIII and a process for producing it |
| ZA842418B (en) | 1983-03-31 | 1984-11-28 | Scripps Clinic Res | Factor viii coagulant polypeptides and monoclonal antibodies to them |
| US4727027A (en) | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| US4748120A (en) | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| AT379510B (en) | 1983-05-20 | 1986-01-27 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING PRAEPARATION |
| DE3318521A1 (en) | 1983-05-20 | 1984-11-22 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | METHOD FOR PRODUCING AN ANTIHAEMOPHILIE FACTOR CONCENTRATE |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| DE3336631A1 (en) | 1983-10-08 | 1985-04-18 | Behringwerke Ag, 3550 Marburg | METHOD FOR THE PASTEURIZATION OF PLASMA OR CONCENTRATES OF THE BLOOD COAGINING FACTORS II, VII, IX AND X |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
| JPS6122022A (en) | 1983-12-28 | 1986-01-30 | Green Cross Corp:The | Method for heat-treating blood plasma protein |
| ATE224445T1 (en) | 1984-01-12 | 2002-10-15 | Chiron Corp | DNA SEQUENCES CODING FOR FACTOR VIIIC AND RELATED DNA CONSTRUCTIONS |
| WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
| AT389815B (en) | 1984-03-09 | 1990-02-12 | Immuno Ag | METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS |
| US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
| JPS60199829A (en) | 1984-03-24 | 1985-10-09 | Nippon Sekijiyuujishiya | Preparation of high-purity antihemophilic globulin |
| US5043428A (en) | 1984-08-31 | 1991-08-27 | Behringwerke Aktiengesellschaft | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production |
| US4543210A (en) | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
| US4613501A (en) | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
| JPS61271222A (en) * | 1985-05-24 | 1986-12-01 | Dainippon Pharmaceut Co Ltd | Human interleukine 1 polypeptide and derivative thereof |
| US4743680A (en) | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
| US4952675A (en) | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
| US4847362A (en) | 1985-02-01 | 1989-07-11 | New York University | Method for purifying antihemophilic factor |
| ATE72838T1 (en) | 1985-04-12 | 1992-03-15 | Genetics Inst | NEW PROCOAGULATION PROTEINS. |
| US4758657A (en) | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
| DE3577801D1 (en) | 1985-08-05 | 1990-06-28 | Immuno Ag | METHOD FOR THE PRODUCTION OF PREPARATIONS BASED ON BLOOD COUPLING FACTORS. |
| AU6487286A (en) | 1985-11-08 | 1987-05-14 | Baxter Travenol Laboratories Inc. | Antihemophilic factor by cold precipitation |
| US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| JPS62195331A (en) | 1986-02-24 | 1987-08-28 | Nippon Sekijiyuujishiya | Production of blood coagulation factor viii pharmaceutical |
| AT390374B (en) | 1986-03-18 | 1990-04-25 | Schwab & Co Gmbh | METHOD FOR PASTEURIZING PLASMA PROTEIN AND PLASMA PROTEIN FRACTIONS |
| DE3609431A1 (en) | 1986-03-20 | 1987-09-24 | Biotest Pharma Gmbh | METHOD FOR PRODUCING A STERILE PRESERVATIVE CONTAINING THE BLOOD coagulation factor VIII |
| US4841023A (en) | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
| AT391808B (en) | 1986-11-03 | 1990-12-10 | Immuno Ag | METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING FRACTION |
| GB8628104D0 (en) | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| ES2006632A6 (en) | 1987-04-21 | 1989-05-01 | Green Cross Corp | Process for heat treating fibrinogen |
| US4876241A (en) | 1987-05-22 | 1989-10-24 | Armour Pharmaceutical Company | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
| IL86417A (en) | 1987-05-22 | 1992-09-06 | Armour Pharma | Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers |
| US4795806A (en) | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
| JPH0387173A (en) | 1987-09-10 | 1991-04-11 | Teijin Ltd | Preparation of human active natural type factor viii c and transformant using the same |
| DE3730533A1 (en) | 1987-09-11 | 1989-03-30 | Biotest Pharma Gmbh | METHOD FOR STERILIZING PLASMA OR PLASMA FACTIONS |
| KR890004724A (en) * | 1987-09-17 | 1989-05-09 | 히사시 미하라 | New protease preparations |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| CA1329760C (en) | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US5177191A (en) | 1987-12-21 | 1993-01-05 | Miles, Inc. | Gel filtration of factor VIII |
| DK18288D0 (en) | 1988-01-15 | 1988-01-15 | Nordisk Gentofte | PROCEDURE FOR PASTEURIZATION OF Aqueous SOLUTIONS OF FACTOR VIII |
| WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
| US4981951A (en) | 1988-04-14 | 1991-01-01 | Miles Inc. | Lectin affinity chromatography of factor VIII |
| FR2632309B1 (en) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | PROCESS FOR THE CHROMATOGRAPHIC PURIFICATION OF PROTEINS, PARTICULARLY FACTOR VIII, AND THE PRODUCTS OBTAINED |
| US5047249A (en) | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
| US5051353A (en) | 1988-08-09 | 1991-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Preservation and restoration of hemoglobin in blood substitutes |
| JPH02157231A (en) * | 1988-12-07 | 1990-06-18 | Bio Kagaku Kenkyusho:Kk | Cytostatic agent |
| DE3904354A1 (en) | 1989-02-14 | 1990-08-16 | Behringwerke Ag | PASTEURIZED, PURIFIED OF WILLEBRAND FACTOR CONCENTRATE AND METHOD FOR THE PRODUCTION THEREOF |
| FR2665449B1 (en) | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | METHOD FOR MANUFACTURING A VON WILLEBRAND FACTOR HAVING VERY HIGH PURITY, MAINLY LACKING AN ANTIHEMOPHILIC FACTOR (FVIIIC), AND VON WILLEBRAND FACTOR THUS OBTAINED, AS WELL AS A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME. |
| US5760183A (en) | 1989-02-17 | 1998-06-02 | Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques | Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same |
| CN1047342A (en) | 1989-05-13 | 1990-11-28 | 杭州市中心血站 | The production of Factor IX and virus inactivating method thereof |
| ES2042138T3 (en) | 1989-05-24 | 1993-12-01 | Miles Inc. | GEL FILTRATION OF FACTOR VIII THERMALLY TREATED. |
| GB8913183D0 (en) * | 1989-06-08 | 1989-07-26 | Central Blood Lab Authority | Chemical products |
| US5138034A (en) | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
| US5062498A (en) | 1989-07-18 | 1991-11-05 | Jaromir Tobias | Hydrostatic power transfer system with isolating accumulator |
| ATE148165T1 (en) | 1989-07-24 | 1997-02-15 | Bayer Ag | STABILIZATION OF HIGHLY PURIFIED PROTEINS |
| DE3926034C3 (en) | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Process for the preparation of a stable factor VIII |
| FR2651437A1 (en) | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | PROCESS FOR PREPARING A CONCENTRATE OF THE VON WILLEBRAND FACTOR VIII-FACTOR COMPLEX OF BLOOD COAGULATION FROM TOTAL PLASMA. |
| DK162233C (en) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII |
| SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
| US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
| DE4001451A1 (en) | 1990-01-19 | 1991-08-01 | Octapharma Ag | STABLE INJECTABLE SOLUTIONS OF FACTOR VIII AND FACTOR IX |
| US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
| US5587490A (en) | 1990-04-16 | 1996-12-24 | Credit Managers Association Of California | Method of inactivation of viral and bacterial blood contaminants |
| US5798238A (en) | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
| AU7875791A (en) * | 1990-05-07 | 1991-11-27 | Exxon Chemical Patents Inc. | Unsaturated alpha-olefin copolymers and method for preparation thereof |
| US5378612A (en) | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
| US5712086A (en) | 1990-05-15 | 1998-01-27 | New York Blood Center, Inc. | Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions |
| US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| FR2662166A1 (en) | 1990-05-18 | 1991-11-22 | Fondation Nale Transfusion San | PROCESS FOR PREPARING HIGHLY HIGH PURITY FACTOR VIII COMPRISING A RAPID IMMUNOADSORPTION STEP |
| IT1248723B (en) | 1990-06-12 | 1995-01-26 | Scalvo S P A | PROCESS FOR THE PURIFICATION OF FACTOR VIII AND FACTOR VIII OBTAINED WITH SUCH PROCESS |
| EP0491895B1 (en) | 1990-07-12 | 1995-07-19 | Dade Produktions AG | FACTOR VIII:Ca CHROMOGENIC ASSAY |
| AU650045B2 (en) | 1990-09-12 | 1994-06-09 | Lifecell Corporation | Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| FR2673632A1 (en) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
| DE4111393A1 (en) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | STABILIZED FACTOR VIII PREPARATIONS |
| SE468480B (en) | 1991-05-24 | 1993-01-25 | Arne Holmgren | Modified thioredoxin and its use |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| US5254350A (en) | 1991-07-22 | 1993-10-19 | Helena Laboratories Corporation | Method of preparing a thromboplastin extract |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| FR2681867B1 (en) | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | FACTOR VIII PURIFICATION PROCESS AND PREPARATIONS OBTAINED. |
| US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
| US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| JPH05331071A (en) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | Lyophilized composition of calcitonin gene-related peptide and stabilization thereof |
| AT399818B (en) | 1992-04-24 | 1995-07-25 | Immuno Ag | METHOD FOR PRODUCING A HIGH PURIFIED VIRUS-SAFE FACTOR VIII PREPARATION |
| US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| WO1993022336A1 (en) | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US5378601A (en) | 1992-07-24 | 1995-01-03 | Montefiore Medical Center | Method of preserving platelets with apyrase and an antioxidant |
| US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
| SK282483B6 (en) * | 1992-10-02 | 2002-02-05 | Genetics Institute, Inc. | Stable composition of coagulating factor viii, its preparation and stabilisation method |
| IT1256622B (en) | 1992-12-04 | 1995-12-12 | Sclavo Spa | PROCESS FOR THE EXTRACTION OF THE FACTOR VIII-FACTOR VON WILLEBRAND (FVIII: C-FVW) FROM TOTAL HUMAN PLASMA. |
| DE4242863A1 (en) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stable lyophilized pharmaceutical preparations of G-CSF |
| WO1994017834A1 (en) | 1993-02-09 | 1994-08-18 | Octapharma Ag | Method for inactivating viruses devoid of lipid envelopes |
| SE9301581D0 (en) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | PROTEIN FORMULATION |
| SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
| US5576291A (en) | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
| US5353835A (en) | 1993-09-23 | 1994-10-11 | Ingersoll-Rand Company | Air tank drain |
| IT1268920B1 (en) | 1994-03-29 | 1997-03-13 | Syfal Srl | ROTARY MACHINE FOR DECORATION-GLAZING IN PARTICULAR CERAMIC TILES. |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US5514781A (en) | 1994-04-11 | 1996-05-07 | Bayer Corporation | Use of azoles as virucidal agents in solutions of biologically active proteins |
| US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| FR2719479B1 (en) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Stable lyophilized formulation comprising a protein: assay kit. |
| ATE235919T1 (en) | 1994-06-02 | 2003-04-15 | Elan Drug Delivery Ltd | METHOD FOR PREVENTING AGGREGATION OF PROTEINS/PEPTIDES DURING REHYDRATION OR DEFROSTING |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| DE4431833C1 (en) | 1994-09-07 | 1995-05-18 | Blutspendedienst Der Drk Lande | Prepn. of an anti-haemophilic factor from a cryo-precipitate |
| GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
| SE9403915D0 (en) | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
| SE503424C2 (en) | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process for purification of recombinant coagulation factor VIII |
| AU4526996A (en) * | 1994-12-28 | 1996-07-19 | Biotime, Inc. | Plasma expanders and blood substitutes |
| GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| SE9501189D0 (en) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
| US5679549A (en) | 1995-05-04 | 1997-10-21 | Bayer Corporation | Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition |
| JP3927248B2 (en) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | HGF lyophilized formulation |
| KR0167677B1 (en) * | 1995-08-31 | 1999-02-01 | 김광호 | Memory test system with pattern generator for multi-bit test |
| SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| ES2099678B1 (en) | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | PROCEDURE FOR THE INACTIVATION OF VIRUSES IN PROTEINS. |
| ATE235814T1 (en) | 1995-11-06 | 2003-04-15 | New York Blood Ct Inc | TREATMENT OF RED BLOOD CELLS TO INACTIVATE VIRIA BY USING PATHALOCYANINS AND RED LIGHT |
| US5659017A (en) | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
| US5925738A (en) | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
| US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
| US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US6586573B1 (en) * | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| CA2378751C (en) | 1999-07-13 | 2012-11-06 | Biovitrum Ab | Stable factor viii compositions |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| MXPA06006886A (en) | 2003-12-19 | 2006-09-04 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor vii polypeptides. |
| EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | Antibody-containing stabilizing preparation |
| JO3324B1 (en) | 2006-04-21 | 2019-03-13 | Amgen Inc | Lyophilized Therapeutic Peptibody Formulations |
| PL2337580T3 (en) | 2008-09-03 | 2012-08-31 | Octapharma Ag | Stabilized compositions for recombinantly produced factor viii |
-
2000
- 2000-02-22 US US09/507,011 patent/US6586573B1/en not_active Expired - Lifetime
- 2000-02-22 PT PT60772290T patent/PT1820516E/en unknown
- 2000-02-22 CA CA2362927A patent/CA2362927C/en not_active Expired - Lifetime
- 2000-02-22 BR BRPI0008405-0B1A patent/BR0008405B1/en not_active IP Right Cessation
- 2000-02-22 CZ CZ20012996A patent/CZ300547B6/en not_active IP Right Cessation
- 2000-02-22 EP EP00907322A patent/EP1154796B1/en not_active Expired - Lifetime
- 2000-02-22 CA CA002634674A patent/CA2634674A1/en not_active Abandoned
- 2000-02-22 CA CA2634664A patent/CA2634664C/en not_active Expired - Lifetime
- 2000-02-22 ES ES06077229T patent/ES2435141T3/en not_active Expired - Lifetime
- 2000-02-22 CN CN2009101711245A patent/CN101683522B/en not_active Expired - Lifetime
- 2000-02-22 AT AT00907322T patent/ATE365052T1/en active
- 2000-02-22 CN CNB008063044A patent/CN100553678C/en not_active Expired - Lifetime
- 2000-02-22 DK DK09075396.3T patent/DK2130554T3/en active
- 2000-02-22 EP EP15154020.0A patent/EP2921180B1/en not_active Expired - Lifetime
- 2000-02-22 WO PCT/US2000/040068 patent/WO2000048635A1/en active Application Filing
- 2000-02-22 PL PL382288A patent/PL203177B1/en unknown
- 2000-02-22 CA CA002634663A patent/CA2634663C/en not_active Expired - Lifetime
- 2000-02-22 AU AU28843/00A patent/AU777972B2/en not_active Expired
- 2000-02-22 PL PL382299A patent/PL203893B1/en unknown
- 2000-02-22 PL PL382300A patent/PL204701B1/en unknown
- 2000-02-22 DK DK10075019.9T patent/DK2193809T3/en active
- 2000-02-22 CZ CZ2008-827A patent/CZ307322B6/en not_active IP Right Cessation
- 2000-02-22 EP EP10075019.9A patent/EP2193809B1/en not_active Expired - Lifetime
- 2000-02-22 ES ES00907322T patent/ES2288843T3/en not_active Expired - Lifetime
- 2000-02-22 DK DK06077229.0T patent/DK1820516T3/en active
- 2000-02-22 CZ CZ2008-828A patent/CZ307715B6/en not_active IP Right Cessation
- 2000-02-22 ES ES09075396T patent/ES2394755T3/en not_active Expired - Lifetime
- 2000-02-22 PL PL356453A patent/PL198123B1/en unknown
- 2000-02-22 RU RU2001125929/15A patent/RU2244556C2/en active
- 2000-02-22 CN CN200910171121A patent/CN101810854A/en active Pending
- 2000-02-22 DK DK00907322T patent/DK1154796T3/en active
- 2000-02-22 PT PT09075396T patent/PT2130554E/en unknown
- 2000-02-22 MX MXPA01008515A patent/MXPA01008515A/en active IP Right Grant
- 2000-02-22 EP EP09075396A patent/EP2130554B1/en not_active Revoked
- 2000-02-22 ES ES10075019.9T patent/ES2541470T3/en not_active Expired - Lifetime
- 2000-02-22 PT PT00907322T patent/PT1154796E/en unknown
- 2000-02-22 PT PT100750199T patent/PT2193809E/en unknown
- 2000-02-22 JP JP2000599425A patent/JP5149470B2/en not_active Expired - Lifetime
- 2000-02-22 EP EP06077229.0A patent/EP1820516B1/en not_active Expired - Lifetime
- 2000-02-22 DE DE60035260T patent/DE60035260T2/en not_active Expired - Lifetime
-
2003
- 2003-07-01 US US10/610,723 patent/US7087723B2/en not_active Expired - Lifetime
-
2006
- 2006-05-15 US US11/434,634 patent/US7247707B2/en not_active Expired - Lifetime
-
2007
- 2007-06-18 US US11/764,770 patent/US8058226B2/en not_active Expired - Lifetime
- 2007-08-07 CY CY20071101050T patent/CY1108030T1/en unknown
- 2007-12-07 HK HK10106491.9A patent/HK1139862A1/en not_active IP Right Cessation
- 2007-12-07 HK HK10100752.6A patent/HK1133583A1/en not_active IP Right Cessation
- 2007-12-07 HK HK07113386.8A patent/HK1106705A1/en not_active IP Right Cessation
-
2008
- 2008-05-01 JP JP2008120035A patent/JP5006832B2/en not_active Expired - Lifetime
- 2008-09-30 JP JP2008255510A patent/JP5140539B2/en not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/250,789 patent/US8372800B2/en not_active Expired - Lifetime
-
2012
- 2012-01-20 JP JP2012009767A patent/JP5596064B2/en not_active Expired - Lifetime
- 2012-12-04 CY CY20121101185T patent/CY1113969T1/en unknown
-
2013
- 2013-02-06 US US13/760,900 patent/US8765665B2/en not_active Expired - Lifetime
- 2013-11-01 JP JP2013227977A patent/JP6038003B2/en not_active Expired - Lifetime
-
2014
- 2014-05-23 US US14/286,391 patent/US9352027B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 JP JP2015031316A patent/JP6155442B2/en not_active Expired - Lifetime
- 2015-11-11 JP JP2015220875A patent/JP6253627B2/en not_active Expired - Lifetime
-
2016
- 2016-02-18 HK HK16101857.2A patent/HK1213801A1/en unknown
- 2016-05-04 US US15/146,835 patent/US9669076B2/en not_active Expired - Lifetime
-
2017
- 2017-04-27 JP JP2017088289A patent/JP2017125076A/en not_active Withdrawn
-
2018
- 2018-07-02 JP JP2018125917A patent/JP2018172413A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9669076B2 (en) | Albumin-free factor VIII formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20131015 |